{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:55:01Z","timestamp":1794048901183,"version":"4.8.0"},"reference-count":775,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jhep.2025.03.018","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T20:02:25Z","timestamp":1746820945000},"page":"502-583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":535,"title":["EASL Clinical Practice Guidelines on the management of hepatitis B virus infection"],"prefix":"10.1016","volume":"83","author":[{"given":"Markus","family":"Cornberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Sandmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Jaroszewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Lemoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabela","family":"Lens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Testoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Lai-Hung Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Paolo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2025.03.018_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jhep.2018.10.011","article-title":"Clinical practice guidelines of the European association for the study of the liver - advancing methodology but preserving practicability","volume":"70","author":"Cornberg","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jhep.2015.04.026","article-title":"Immigration and viral hepatitis","volume":"63","author":"Sharma","year":"2015","journal-title":"J Hepatol"},{"issue":"23","key":"10.1016\/j.jhep.2025.03.018_bib4","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"S2468\u20131253","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib5","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib6","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1097\/HEP.0000000000000459","article-title":"Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase","volume":"78","author":"Huang","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib7","article-title":"Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: a systematic review and meta-analysis","author":"Che-To Lai","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.cgh.2014.07.019","article-title":"Outcomes of patients with chronic hepatitis B who do not meet criteria for antiviral treatment at presentation","volume":"13","author":"Yapali","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib9","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","article-title":"The role of quantitative hepatitis B surface antigen revisited","volume":"66","author":"Cornberg","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib10","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1537-2995.2007.01234.x","article-title":"Lengths of hepatitis B viremia and antigenemia in blood donors: preliminary evidence of occult (hepatitis B surface antigen-negative) infection in the acute stage","volume":"47","author":"Yoshikawa","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.jhep.2025.03.018_bib11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2019.03.034","article-title":"Update of the statements on biology and clinical impact of occult hepatitis B virus infection","volume":"71","author":"Raimondo","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29144","article-title":"Ultrasensitive PCR system for HBV DNA detection: risk stratification for occult hepatitis B virus infection in English blood donors","volume":"95","author":"Fu","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2025.03.018_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104507","article-title":"The contribution of more sensitive hepatitis B surface antigen assays to detecting and monitoring hepatitis B infection","volume":"129","author":"Pronier","year":"2020","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jhep.2025.03.018_bib14","doi-asserted-by":"crossref","first-page":"E263","DOI":"10.1111\/hepr.12979","article-title":"Analysis of hepatitis B surface antigen (HBsAg) using high-sensitivity HBsAg assays in hepatitis B virus carriers in whom HBsAg seroclearance was confirmed by conventional assays","volume":"48","author":"Ozeki","year":"2018","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2025.03.018_bib15","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1002\/jmv.20611","article-title":"Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection","volume":"78","author":"Scheiblauer","year":"2006","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2025.03.018_bib16","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jcv.2012.01.003","article-title":"Variable capacity of 13 hepatitis B virus surface antigen assays for the detection of HBsAg mutants in blood samples","volume":"53","author":"Servant-Delmas","year":"2012","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jhep.2025.03.018_bib17","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1111\/trf.18018","article-title":"International review of blood donation screening for anti-HBc and occult hepatitis B virus infection","volume":"64","author":"Fu","year":"2024","journal-title":"Transfusion"},{"key":"10.1016\/j.jhep.2025.03.018_bib18","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/hep.28503","article-title":"The many faces of positive hepatitis B surface antigen","volume":"64","author":"Tang","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib19","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.ekir.2021.05.021","article-title":"False-positive hepatitis B antigenemia after vaccination in a patient with CKD","volume":"6","author":"Khoo","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jhep.2025.03.018_bib20","article-title":"An interesting case of isolated false-reactive hepatitis B surface antigen","volume":"2021","author":"Costa","year":"2021","journal-title":"Case Rep Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib21","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1046\/j.1537-2995.1996.36111297091735.x","article-title":"False-positive hepatitis B surface antigen screening test results in patients receiving granulocyte-colony-stimulating factor","volume":"36","author":"Mair","year":"1996","journal-title":"Transfusion"},{"key":"10.1016\/j.jhep.2025.03.018_bib22","doi-asserted-by":"crossref","first-page":"6670","DOI":"10.4049\/jimmunol.0803683","article-title":"Interaction of the hepatitis B core antigen and the innate immune system","volume":"182","author":"Lee","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2025.03.018_bib23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1128\/jcm.6.3.209-211.1977","article-title":"Persistence of serum antibody to hepatitis B core antigen","volume":"6","author":"Hansson","year":"1977","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jhep.2025.03.018_bib24","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s11901-020-00522-0","article-title":"Hepatitis B core antibody: role in clinical practice in 2020","volume":"19","author":"Gish","year":"2020","journal-title":"Curr Hepatol Rep"},{"key":"10.1016\/j.jhep.2025.03.018_bib25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hep.29082","article-title":"Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis","volume":"66","author":"Paul","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib26","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/oxfordjournals.aje.a115651","article-title":"The epidemiology of hepatitis B virus among family members in the Middle East","volume":"132","author":"Toukan","year":"1990","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jhep.2025.03.018_bib27","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1053\/j.gastro.2009.10.039","article-title":"Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective","volume":"138","author":"Veldhuijzen","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207037","article-title":"Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country","volume":"13","author":"Suijkerbuijk","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2025.03.018_bib29","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cld.2023.05.007","article-title":"Maternal-to-Child transmission of hepatitis B virus and hepatitis delta virus","volume":"27","author":"Aliasi-Sinai","year":"2023","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib30","article-title":"Hepatitis B perinatal vaccine information","year":"2025","journal-title":"Hepat B"},{"key":"10.1016\/j.jhep.2025.03.018_bib31","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.adaj.2016.03.020","article-title":"Transmission of blood-borne pathogens in US dental health care settings: 2016 update","volume":"147","author":"Cleveland","year":"2016","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.jhep.2025.03.018_bib32","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.30.1800614","article-title":"Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU\/EEA: a systematic review","volume":"24","author":"Mason","year":"2019","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jhep.2025.03.018_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2025.03.018_bib34","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2011.06.036","article-title":"Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma","volume":"141","author":"Chen","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib35","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41575-022-00649-z","article-title":"A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook","volume":"19","author":"Kramvis","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2021.114063","article-title":"Performance evaluation of Xpert HBV viral load (VL) assay: point-of-care molecular test to strengthen and decentralize management of chronic hepatitis B (CHB) infection","volume":"290","author":"Gupta","year":"2021","journal-title":"J Virol Methods"},{"key":"10.1016\/j.jhep.2025.03.018_bib38","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1002\/jmv.26662","article-title":"Real-world application of the Xpert\u00ae HBV viral load assay on serum and dried blood spots","volume":"93","author":"Jackson","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2025.03.018_bib39","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jhep.2018.05.024","article-title":"Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa","volume":"69","author":"Shimakawa","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcv.2018.10.007","article-title":"Usefulness of a serial algorithm of HBsAg and HBeAg rapid diagnosis tests to detect pregnant women at risk of HBV mother-to-child transmission in Cambodia, the ANRS 12328 pilot study","volume":"109","author":"S\u00e9g\u00e9ral","year":"2018","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jhep.2025.03.018_bib41","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.3390\/diagnostics13193144","article-title":"Evaluation of the diagnostic performances of the SD-Bioline\u00aeHBeAg rapid test used routinely for the management of HBV-infected individuals in Burkina Faso","volume":"13","author":"Dera","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jhep.2025.03.018_bib42","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4269\/ajtmh.18-0116","article-title":"Poor Sensitivity of Commercial Rapid Diagnostic Tests for Hepatitis B e Antigen in Senegal, West Africa","volume":"99","author":"Seck","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jhep.2025.03.018_bib43","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s12072-009-9140-3","article-title":"HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B","volume":"3","author":"Liaw","year":"2009","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib44","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/j.gastro.2010.04.052","article-title":"Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers","volume":"139","author":"Brunetto","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib45","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hep.28552","article-title":"Serum levels of hepatitis B surface antigen and DNA can predict inactive carriers with low risk of disease progression","volume":"64","author":"Liu","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib46","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cgh.2016.01.019","article-title":"Repeated measurements of hepatitis B surface antigen identify carriers of inactive HBV during long-term follow-up","volume":"14","author":"Brouwer","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib47","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/apt.16258","article-title":"Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis","volume":"53","author":"Brunetto","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib48","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","article-title":"High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load","volume":"142","author":"Tseng","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043087","article-title":"High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B","volume":"7","author":"Seto","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2025.03.018_bib50","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jhep.2013.01.028","article-title":"Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-na\u00efve, e antigen-positive patients","volume":"58","author":"Martinot-Peignoux","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib51","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/apt.17915","article-title":"Persistently high HBsAg levels during HBeAg-seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients","volume":"59","author":"Lin","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib52","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s12072-012-9382-3","article-title":"Combining the HBsAg decline and HBV DNA levels predicts clinical outcomes in patients with spontaneous HBeAg seroconversion","volume":"7","author":"Yang","year":"2013","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib53","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1053\/j.gastro.2011.04.046","article-title":"Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters","volume":"141","author":"Tseng","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib54","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/hep.23803","article-title":"A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B","volume":"52","author":"Chan","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib55","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jhep.2023.06.002","article-title":"2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference Faculty. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference","volume":"79","author":"Ghany","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib56","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hep.1840010307","article-title":"Presence and meaning of anti-HBc IgM as determined by ELISA in patients with acute type B hepatitis and healthy HBsAg carriers","volume":"1","author":"Kryger","year":"1981","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib57","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3350\/cmh.2019.0060","article-title":"The dilemma of differentiating between acute hepatitis B and chronic hepatitis B with acute exacerbation: is quantitative serology the answer?","volume":"26","author":"Lall","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib58","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cgh.2020.04.045","article-title":"Hepatitis B core-related antigen to indicate high viral load: systematic review and meta-analysis of 10,397 individual participants","volume":"19","author":"Yoshida","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib59","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.cgh.2022.05.026","article-title":"Rapid point-of-care test for hepatitis B core-related antigen to diagnose high viral load in resource-limited settings","volume":"21","author":"Shimakawa","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib60","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000322","article-title":"Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study","volume":"93","author":"Jia","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhep.2025.03.018_bib61","article-title":"Total hepatitis B core antigen antibody, a quantitative non-invasive marker of hepatitis B virus induced liver disease","volume":"10","author":"Yuan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2025.03.018_bib62","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhep.2018.02.033","article-title":"Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection","volume":"69","author":"Yang","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib63","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1056\/NEJMra2212151","article-title":"Hepatitis D virus infection","volume":"389","author":"Asselah","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib64","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL Clinical Practice Guidelines on hepatitis delta virus","volume":"79","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib65","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib66","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jhep.2023.10.043","article-title":"Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories","volume":"80","author":"Observatory Collaborators","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib67","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.3390\/v15122345","article-title":"Diagnostic efficacy of serological antibody detection tests for hepatitis delta virus: a systematic review and meta-analysis","volume":"15","author":"Pan","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.jhep.2025.03.018_bib68","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/HEP.0000000000000584","article-title":"HDV RNA assays: performance characteristics, clinical utility, and challenges","volume":"81","author":"Wedemeyer","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib69","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.3390\/v13122371","article-title":"A rapid point-of-care test for the Serodiagnosis of hepatitis delta virus infection","volume":"13","author":"Lempp","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jhep.2025.03.018_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2021.104932","article-title":"Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: a European multicenter study","volume":"142","author":"Stelzl","year":"2021","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jhep.2025.03.018_bib71","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1097\/HEP.0000000000000975","article-title":"Letter to the Editor: the WHO HDV RNA international standard does not reflect variability of real-world samples","volume":"81","author":"Sandmann","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib72","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/hiv.13542","article-title":"Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023","volume":"24","author":"Ambrosioni","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib73","series-title":"Consolidated guidelines on differentiated HIV testing services","year":"2024"},{"key":"10.1016\/j.jhep.2025.03.018_bib74","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1186\/s12879-017-2773-2","article-title":"Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-analysis and review of the literature","volume":"17","author":"Tang","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib75","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jhep.2018.03.005","article-title":"EASL clinical practice guidelines on hepatitis E virus infection","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib76","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3406789","article-title":"Transient elastography for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis","volume":"2018","author":"Qi","year":"2018","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib77","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/apt.13488","article-title":"Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B","volume":"43","author":"Li","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib78","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/HEP.0000000000000852","article-title":"Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: a systematic review supporting the AASLD Practice Guideline","volume":"81","author":"Duarte-Rojo","year":"2025","journal-title":"Hepatology"},{"issue":"24","key":"10.1016\/j.jhep.2025.03.018_bib79","article-title":"Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: a systematic review and meta-analysis","volume":"S2468\u20131253","author":"Liguori","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib80","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib81","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2020.11.050","article-title":"Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease","volume":"74","author":"Papatheodoridi","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib82","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jhep.2009.05.031","article-title":"Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension","volume":"51","author":"Manolakopoulos","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib83","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2018.11.053","article-title":"Validation of Baveno VI criteria for screening and surveillance of Esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy","volume":"156","author":"Thabut","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib84","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - Renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib85","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jhep.2022.10.030","article-title":"Baveno VII algorithm outperformed other models in ruling out high-risk varices in individuals with HBV-related cirrhosis","volume":"78","author":"Zhang","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib86","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/MEG.0b013e32835cb5dd","article-title":"Evaluation of seven noninvasive models in staging liver fibrosis in patients with chronic hepatitis B virus infection","volume":"25","author":"Ma","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib87","article-title":"The diagnostic value of the FIB-4 index for staging hepatitis B-related fibrosis: a meta-analysis","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2025.03.018_bib88","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S2468-1253(19)30087-1","article-title":"Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study","volume":"4","author":"Sonneveld","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib89","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/hep.27382","article-title":"Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis","volume":"61","author":"Xiao","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib90","unstructured":"Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection n.d. https:\/\/www.who.int\/publications\/i\/item\/9789240090903 (accessed August 12, 2024)."},{"key":"10.1016\/j.jhep.2025.03.018_bib91","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jhep.2014.06.027","article-title":"Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest\u00ae) and elastography (FibroScan\u00ae)","volume":"61","author":"Poynard","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib92","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMra1610570","article-title":"Use of liver imaging and biopsy in clinical practice","volume":"377","author":"Tapper","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib93","first-page":"275","article-title":"Longitudinal observation of viral load changes in untreated HBeAg negative chronic hepatitis B","volume":"76","author":"Croagh","year":"2013","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1016\/j.jhep.2025.03.018_bib94","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2893.2007.00957.x","article-title":"Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection","volume":"15","author":"Papatheodoridis","year":"2008","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.03.018_bib95","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/ajg.2009.187","article-title":"Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus","volume":"104","author":"Chu","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib96","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","article-title":"Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B","volume":"35","author":"Hsu","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib97","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/hep.23348","article-title":"Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B","volume":"51","author":"Chen","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib98","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.clinre.2019.10.009","article-title":"Predictive factors for risk of hepatocellular carcinoma in immune inactive chronic hepatitis B","volume":"44","author":"Seo","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib99","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12072-020-10113-2","article-title":"Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients","volume":"15","author":"Liu","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib100","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/liv.13416","article-title":"Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: benign course towards HBsAg clearance","volume":"37","author":"Oliveri","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib101","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjmed.2003.12.040","article-title":"Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels","volume":"116","author":"Chu","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib102","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jcv.2007.04.008","article-title":"Presence of hepatitis B virus core promoter mutations pre-seroconversion predict persistent viral replication after HBeAg loss","volume":"39","author":"Ferns","year":"2007","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jhep.2025.03.018_bib103","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1038\/ajg.2014.301","article-title":"Hepatitis B surface antigen seroclearance: relationship to hepatitis B e-antigen seroclearance and hepatitis B e-antigen-negative hepatitis","volume":"109","author":"Fung","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib104","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/hep.21612","article-title":"HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up","volume":"45","author":"Chu","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib105","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/hep.26385","article-title":"Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles","volume":"58","author":"Lee","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib106","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/jgh.14103","article-title":"Non-invasive assessments for liver fibrosis: the crystal ball we long for","volume":"33","author":"Wong","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib107","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/ajg.2017.389","article-title":"Prognostic value of controlled attenuation parameter by transient elastography","volume":"112","author":"Liu","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib108","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jhep.2013.09.029","article-title":"Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B","volume":"60","author":"Wong","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib109","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA Level","volume":"295","author":"Chen","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jhep.2025.03.018_bib110","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib111","doi-asserted-by":"crossref","first-page":"49299","DOI":"10.18632\/oncotarget.10335","article-title":"The contribution of serum hepatitis B virus load in the carcinogenesis and prognosis of hepatocellular carcinoma: evidence from two meta-analyses","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2025.03.018_bib112","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1002\/hep.22884","article-title":"Hepatitis B virus DNA levels and outcomes in chronic hepatitis B","volume":"49","author":"Chen","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib113","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib114","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jhep.2018.01.031","article-title":"Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population","volume":"68","author":"Papatheodoridis","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib115","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"The Lancet"},{"key":"10.1016\/j.jhep.2025.03.018_bib116","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib117","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/apt.12344","article-title":"Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B","volume":"38","author":"Singal","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib118","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.14309\/ajg.0000000000001195","article-title":"Antiviral therapy reduces risk of cirrhosis in noncirrhotic HBV patients among 4 urban safety-net health systems","volume":"116","author":"Wong","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib119","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/infdis\/jiy391","article-title":"Reduced incidence of hepatocellular carcinoma in cirrhotic and noncirrhotic patients with chronic hepatitis B treated with tenofovir-A propensity score-matched study","volume":"219","author":"Nguyen","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib120","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/gutjnl-2014-307023","article-title":"Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians","volume":"64","author":"Arends","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.03.018_bib121","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jhep.2010.02.035","article-title":"Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review","volume":"53","author":"Papatheodoridis","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib122","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/hep.27889","article-title":"Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load","volume":"62","author":"Sinn","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib123","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/hep.28916","article-title":"Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment","volume":"66","author":"Kim","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib124","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/gutjnl-2012-302024","article-title":"Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis","volume":"62","author":"Zoutendijk","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.03.018_bib125","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.14309\/ajg.0000000000002181","article-title":"Low level of hepatitis B viremia compared with undetectable viremia increases the risk of hepatocellular carcinoma in patients with untreated compensated cirrhosis","volume":"118","author":"Yang","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib126","first-page":"850","article-title":"Chronic hepatitis B infection with low level viremia correlates with the progression of the liver disease","volume":"9","author":"Zhang","year":"2021","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib127","doi-asserted-by":"crossref","first-page":"288","DOI":"10.14309\/ajg.0000000000001497","article-title":"Episodic detectable viremia does not affect prognosis in untreated compensated cirrhosis with serum hepatitis B virus DNA <2,000 IU\/ml","volume":"117","author":"Lee","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib128","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1097\/HEP.0000000000000037","article-title":"Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis","volume":"77","author":"Huang","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib129","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis b: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.03.018_bib130","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1053\/j.gastro.2008.07.008","article-title":"HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma","volume":"135","author":"Yuen","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","author":"Yip","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib132","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/apt.16659","article-title":"Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B","volume":"55","author":"Vittal","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib133","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/apt.13621","article-title":"Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance","volume":"43","author":"Gounder","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib134","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"2019 EASL-AASLD HBV treatment endpoints conference faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV treatment endpoints conference","volume":"72","author":"Cornberg","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib135","article-title":"Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients","author":"Yip","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib136","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.cgh.2019.07.018","article-title":"Durability of spontaneous and treatment-related loss of hepatitis B s antigen","volume":"18","author":"Alawad","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib137","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJM199605303342202","article-title":"Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B","volume":"334","author":"Niederau","year":"1996","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib138","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2006.08.021","article-title":"Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma","volume":"46","author":"Lin","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib139","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/jhep.2001.25273","article-title":"Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications","volume":"34","author":"Yuen","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib140","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2018.05.009","article-title":"Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B","volume":"69","author":"Wong","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib141","doi-asserted-by":"crossref","first-page":"406","DOI":"10.14309\/ajg.0000000000000490","article-title":"Earlier alanine aminotransferase normalization during antiviral treatment is independently associated with lower risk of hepatocellular carcinoma in chronic hepatitis B","volume":"115","author":"Choi","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib142","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.cgh.2017.01.032","article-title":"Factors associated with persistent increase in level of alanine aminotransferase in patients with chronic hepatitis B receiving oral antiviral therapy","volume":"15","author":"Jacobson","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib143","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/apt.17658","article-title":"Systematic review with meta-analysis: significant histological changes among treatment-na\u00efve chronic hepatitis B patients with normal alanine aminotransferase levels by different criteria","volume":"58","author":"Li","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib144","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.3390\/jcm11216247","article-title":"Extrahepatic manifestations of chronic HBV infection and the role of antiviral therapy","volume":"11","author":"Mazzaro","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib145","doi-asserted-by":"crossref","first-page":"253","DOI":"10.14309\/ajg.0000000000001575","article-title":"Hepatitis B virus infection and extra-hepatic manifestations: a systemic disease","volume":"117","author":"Cacoub","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib146","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/v13061032","article-title":"Hepatitis B virus-related cryoglobulinemic vasculitis: review of the literature and long-term follow-up analysis of 18 patients treated with nucleos(t)ide analogues from the Italian study group of cryoglobulinemia (GISC)","volume":"13","author":"Mazzaro","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jhep.2025.03.018_bib147","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.rdc.2009.03.006","article-title":"Hepatitis B-related autoimmune manifestations","volume":"35","author":"Cacoub","year":"2009","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jhep.2025.03.018_bib148","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/s12072-021-10240-4","article-title":"Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis","volume":"15","author":"Wu","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib149","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1186\/s12889-023-17263-6","article-title":"Experience and impact of stigma in people with chronic hepatitis B: a qualitative study in Asia, Europe, and the United States","volume":"24","author":"Toumi","year":"2024","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jhep.2025.03.018_bib150","article-title":"The impact of living with chronic hepatitis B on quality of life: implications for clinical management","volume":"10","author":"Ibrahim","year":"2023","journal-title":"J Patient Exp"},{"key":"10.1016\/j.jhep.2025.03.018_bib151","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12939-022-01677-6","article-title":"The unvirtuous cycle of discrimination affecting people with hepatitis B: a multi-country qualitative assessment of key-informant perspectives","volume":"21","author":"Freeland","year":"2022","journal-title":"Int J Equity Health"},{"key":"10.1016\/j.jhep.2025.03.018_bib152","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s41687-021-00398-8","article-title":"Health-related quality of life for adults living with hepatitis B in the United States: a qualitative assessment","volume":"5","author":"Freeland","year":"2021","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.jhep.2025.03.018_bib153","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/jvh.13894","article-title":"Chronic hepatitis B beyond clinical burden: psychosocial effects and impact on quality of life","volume":"31","author":"Natour","year":"2024","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.03.018_bib154","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000360949","article-title":"Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy","volume":"57","author":"Gerlich","year":"2014","journal-title":"Intervirology"},{"key":"10.1016\/j.jhep.2025.03.018_bib155","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.antiviral.2003.08.014","article-title":"Doctor to patient transmission of hepatitis B virus: implications of HBV DNA levels and potential new solutions","volume":"60","author":"Buster","year":"2003","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhep.2025.03.018_bib156","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1186\/s12889-021-11093-0","article-title":"Common concerns, barriers to care, and the lived experience of individuals with hepatitis B: a qualitative study","volume":"21","author":"Freeland","year":"2021","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jhep.2025.03.018_bib157","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib158","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hep.24361","article-title":"Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib159","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jhep.2009.11.007","article-title":"Efficacy of entecavir in treatment-na\u00efve patients with hepatitis B virus-related decompensated cirrhosis","volume":"52","author":"Shim","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib160","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1365-2893.2012.01600.x","article-title":"Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-na\u00efve patients with HBV-related decompensated cirrhosis","volume":"19","author":"Chan","year":"2012","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.03.018_bib161","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/liv.13142","article-title":"Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis","volume":"36","author":"Raffetti","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib162","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/infdis\/jiab241","article-title":"Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B","volume":"224","author":"Hsu","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib163","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2012.02.007","article-title":"High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load","volume":"142","author":"Tseng","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib164","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2353","article-title":"Hepatitis B virus core-related antigen (HBcrAg) as a prognostic marker for the development of hepatocellular carcinoma: a mini systematic review of the literature","volume":"32","author":"Afifi","year":"2022","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.jhep.2025.03.018_bib165","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/jgh.16558","article-title":"Role of hepatitis B core-related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: a systemic review and meta-analysis","volume":"39","author":"Cao","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib166","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score","volume":"12","author":"Yang","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2025.03.018_bib167","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107177","article-title":"Large variations in risk of hepatocellular carcinoma and mortality in treatment na\u00efve hepatitis B patients: systematic review with meta-analyses","volume":"9","author":"Thiele","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2025.03.018_bib168","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3350\/cmh.2021.0281","article-title":"The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection","volume":"28","author":"Yu","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib169","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jhep.2008.07.023","article-title":"Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B","volume":"50","author":"Yuen","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib170","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/jvh.13029","article-title":"Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: results of ANRS CO12 CirVir cohort","volume":"26","author":"Brichler","year":"2019","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.03.018_bib171","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12885-022-09413-7","article-title":"Risk of hepatocellular carcinoma in antiviral treatment-na\u00efve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis","volume":"22","author":"Huang","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhep.2025.03.018_bib172","article-title":"On-treatment risks of cirrhosis and hepatocellular carcinoma among a large cohort of predominantly non-Asian patients with non-cirrhotic chronic hepatitis B","volume":"5","author":"Yang","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.018_bib173","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111912","article-title":"Liver stiffness measurement among patients with chronic hepatitis B and C: results from a 5-year prospective study","volume":"9","author":"Christiansen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2025.03.018_bib174","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S1473-3099(20)30692-7","article-title":"Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial","volume":"21","author":"Hsu","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib175","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.3390\/jcm8091445","article-title":"Low alanine aminotransferase cut-off for predicting liver outcomes; A nationwide population-based longitudinal cohort study","volume":"8","author":"Park","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib176","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/hep.23200","article-title":"Variability in the upper limit of normal for serum alanine aminotransferase levels: a statewide study","volume":"50","author":"Dutta","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib177","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0168-8278(01)00266-5","article-title":"Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study","volume":"36","author":"Brunetto","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib178","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jamaoncol.2018.0035","article-title":"Association of high body mass index and hepatocellular carcinoma in patients with chronic hepatitis B virus infection: a Korean population-based cohort study","volume":"4","author":"Kim","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2025.03.018_bib179","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1158\/1055-9965.EPI-08-1131","article-title":"The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses","volume":"18","author":"Wang","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jhep.2025.03.018_bib180","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s12072-023-10545-6","article-title":"Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B","volume":"17","author":"Huang","year":"2023","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib181","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1053\/j.gastro.2017.07.001","article-title":"Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: a large cohort study","volume":"153","author":"Yu","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib182","article-title":"All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease","author":"Huang","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib183","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2147\/CMAR.S188238","article-title":"Type 2 diabetes mellitus increases the risk of hepatocellular carcinoma in subjects with chronic hepatitis B virus infection: a meta-analysis and systematic review","volume":"11","author":"Tan","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jhep.2025.03.018_bib184","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/pubmed\/fdad214","article-title":"Interaction between hepatitis B, hepatitis C and smoking in the development of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"46","author":"Shadi","year":"2024","journal-title":"J Public Health (Oxf)"},{"key":"10.1016\/j.jhep.2025.03.018_bib185","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2010.01.042","article-title":"Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death","volume":"138","author":"Chen","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib186","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/1055-9965.EPI-09-1297","article-title":"Interaction between cigarette smoking and hepatitis B and C virus infection on the risk of liver cancer: a meta-analysis","volume":"19","author":"Chuang","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jhep.2025.03.018_bib187","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/ijc.31181","article-title":"Interaction between tobacco smoking and hepatitis B virus infection on the risk of liver cancer in a Chinese population","volume":"142","author":"Liu","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhep.2025.03.018_bib188","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/hep.32792","article-title":"Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: a systematic review and meta-analysis","volume":"77","author":"Mao","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib189","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3350\/cmh.2023.0004","article-title":"Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis","volume":"29","author":"Wong","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib190","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1002\/hep.31612","article-title":"Association of metabolic risk factors with risks of cancer and all-cause mortality in patients with chronic hepatitis B","volume":"73","author":"Lee","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib191","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1002\/hep4.1974","article-title":"Chronic hepatitis B virus infection and the risk of hepatocellular carcinoma by age and country of origin in people living in Sweden: a national register study","volume":"6","author":"Duberg","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.03.018_bib192","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jhep.2008.08.016","article-title":"The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States","volume":"50","author":"Hassan","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib193","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.cgh.2013.04.043","article-title":"Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma","volume":"11","author":"Loomba","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib194","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cncr.30246","article-title":"Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States","volume":"123","author":"Yang","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2025.03.018_bib195","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jhep.2023.10.019","article-title":"Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe","volume":"80","author":"Patmore","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib196","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021436","article-title":"Hepatitis B virus genotypes and variants","volume":"5","author":"Lin","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib197","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1002\/hep.32065","article-title":"HBV genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for HCC: the hepatitis B Alaska study","volume":"74","author":"McMahon","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib198","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.ejca.2012.02.009","article-title":"Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis","volume":"48","author":"Liu","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2025.03.018_bib199","article-title":"Hepatitis B virus preS2\u039438-55 variants: a newly identified risk factor for hepatocellular carcinoma","volume":"2","author":"Cohen","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.018_bib200","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2188\/jea.JE20220262","article-title":"Exposure to PM2.5 metal constituents and liver cancer risk in REVEAL-HBV","volume":"34","author":"Lu","year":"2024","journal-title":"J Epidemiol"},{"key":"10.1016\/j.jhep.2025.03.018_bib201","article-title":"Role of air pollution in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide\/nucleoside analogues","author":"Jang","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib202","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1136\/gutjnl-2015-309892","article-title":"Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from the Gambia","volume":"65","author":"Shimakawa","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.03.018_bib203","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.5718","article-title":"Associations between hepatitis B virus infection and risk of all cancer types","volume":"2","author":"Song","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhep.2025.03.018_bib204","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.21.01285","article-title":"Association of chronic hepatitis B infection and antiviral treatment with the development of the extrahepatic malignancies: a nationwide cohort study","volume":"40","author":"Lee","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.03.018_bib205","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s11606-012-2077-6","article-title":"Shared decision making: a model for clinical practice","volume":"27","author":"Elwyn","year":"2012","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib206","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1056\/NEJMp1109283","article-title":"Shared decision making--pinnacle of patient-centered care","volume":"366","author":"Barry","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib207","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/apt.15725","article-title":"Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients","volume":"51","author":"Kim","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib208","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1053\/j.gastro.2019.08.028","article-title":"High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load","volume":"157","author":"Tseng","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib209","article-title":"HBcrAg-based risk score performs better than the HBV DNA-based scores for HCC prediction in grey zone patients who are HBeAg-negative","volume":"6","author":"Tseng","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.018_bib210","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1440-1746.2002.02737.x","article-title":"Hepatitis B viral genotypes: clinical relevance and molecular characteristics","volume":"17","author":"Kao","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib211","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/gut.2007.119859","article-title":"Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B\/C, specific mutations of enhancer II\/core promoter\/precore regions and HBV DNA levels","volume":"57","author":"Yuen","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.03.018_bib212","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2020.02.030","article-title":"Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies","volume":"73","author":"Alfaiate","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib213","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.13577","article-title":"Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: a systematic review and meta-analysis of longitudinal studies","author":"Kamal","year":"2021","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.03.018_bib214","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262903","article-title":"Hepatitis B, C and D virus infections and risk of hepatocellular carcinoma in Africa: a meta-analysis including sensitivity analyses for studies comparable for confounders","volume":"17","author":"Mbaga","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2025.03.018_bib215","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/hep.31839","article-title":"Risk of HCC with hepatitis B viremia among HIV\/HBV-coinfected persons in North America","volume":"74","author":"Kim","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib216","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/hep.24794","article-title":"Family history of liver cancer and hepatocellular carcinoma","volume":"55","author":"Turati","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib217","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/gut.2004.052167","article-title":"Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study","volume":"54","author":"Davila","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.03.018_bib218","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2023.09.011","article-title":"PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B","volume":"80","author":"Chun","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib219","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/hep.32716","article-title":"Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes","volume":"77","author":"Mak","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib220","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2016.07.012","article-title":"HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant","volume":"151","author":"Mason","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib221","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1053\/j.gastro.2012.06.009","article-title":"Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B","volume":"143","author":"Kennedy","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib222","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1093\/cid\/ciac383","article-title":"Effect of antiviral treatment on hepatitis B virus integration and hepatocyte clonal expansion","volume":"76","author":"Chow","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib223","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2021.12.286","article-title":"Inhibition of viral replication reduces transcriptionally active distinct hepatitis B virus integrations with implications on host gene dysregulation","volume":"162","author":"Hsu","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib224","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(24)00431-X","article-title":"Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial","author":"Lim","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib225","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jhep.2007.07.022","article-title":"The clinical significance of persistently normal ALT in chronic hepatitis B infection","volume":"47","author":"Lai","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib226","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/hep.21724","article-title":"Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase","volume":"46","author":"Hui","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib227","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.cgh.2007.01.005","article-title":"Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome","volume":"5","author":"Andreani","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib228","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1007\/s10620-021-07009-y","article-title":"Liver fibrosis in the natural course of chronic hepatitis B viral infection: a systematic review with meta-analysis","volume":"67","author":"Lin","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2025.03.018_bib229","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2014.01.044","article-title":"Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA","volume":"146","author":"Chan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib230","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjmed.2003.12.040","article-title":"Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels","volume":"116","author":"Chu","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib231","doi-asserted-by":"crossref","DOI":"10.3350\/cmh.2024.0252","article-title":"Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B","author":"Kim","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib232","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/HEP.0000000000000752","article-title":"Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: a multinational cohort study of HBeAg-positive patients","volume":"80","author":"Choi","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib233","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/gutjnl-2017-314904","article-title":"High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B","volume":"67","author":"Kim","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.03.018_bib234","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/07853890310021580","article-title":"Seropositivity of hepatitis B e antigen and hepatocellular carcinoma","volume":"36","author":"You","year":"2004","journal-title":"Ann Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib235","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1053\/j.gastro.2008.02.075","article-title":"Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT","volume":"134","author":"Kumar","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib236","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0168-8278(97)80263-2","article-title":"Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b","volume":"26","author":"Kruger","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib237","first-page":"53","article-title":"[Viral replication and hepatic manifestations in 7 cases of periarteritis nodosa associated with hepatitis B virus]","volume":"10","author":"Ouzan","year":"1986","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.jhep.2025.03.018_bib238","first-page":"119","article-title":"Hepatitis B viremia manifesting as polyarteritis nodosa and secondary membranous nephropathy","volume":"5","author":"Balwani","year":"2016","journal-title":"J Nephropharmacol"},{"key":"10.1016\/j.jhep.2025.03.018_bib239","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/00042737-200205000-00016","article-title":"Hepatitis B associated fulminant polyarteritis nodosa: successful treatment with pulse cyclophosphamide, prednisolone and lamivudine following emergency surgery","volume":"14","author":"Lau","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib240","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/hep.22878","article-title":"Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time","volume":"49","author":"Tai","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib241","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S2468-1253(24)00226-7","article-title":"Clinical outcomes of untreated adults living with chronic hepatitis B in the Gambia: an analysis of data from the prospective PROLIFICA cohort study","volume":"9","author":"Ndow","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib242","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000196","article-title":"Incidence, factors, and patient-level data for spontaneous HBsAg seroclearance: a cohort study of 11,264 patients","volume":"11","author":"Yeo","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib243","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1053\/j.gastro.2010.04.048","article-title":"Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study","volume":"139","author":"Liu","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib244","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2025.101391","article-title":"Prediction of long-term HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients","author":"Lee","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.018_bib245","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jhep.2011.11.030","article-title":"Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review","volume":"57","author":"Papatheodoridis","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib246","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/infdis\/jit209","article-title":"Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers","volume":"208","author":"Tseng","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib247","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/j.gastro.2004.06.021","article-title":"Natural history of chronic HBV carriers in Northern Italy: morbidity and mortality after 30 years","volume":"127","author":"Manno","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib248","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jhep.2016.03.013","article-title":"HBcrAg predicts hepatocellular carcinoma development: an analysis using time-dependent receiver operating characteristics","volume":"65","author":"Tada","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib249","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1053\/j.gastro.2009.01.011","article-title":"Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients","volume":"136","author":"Kumar","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib250","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1055\/s-2007-984960","article-title":"[Hepatitis B associated polyarteriitis nodosa with cerebral vasculitis]","volume":"132","author":"Kohlhaas","year":"2007","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.jhep.2025.03.018_bib251","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1056\/NEJM199701163360304","article-title":"Transmission of hepatitis B to patients from four infected surgeons without hepatitis B e antigen","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib252","doi-asserted-by":"crossref","first-page":"486","DOI":"10.14309\/ajg.0000000000002468","article-title":"Long-term treatment with tenofovir alafenamide for chronic hepatitis B results in high rates of viral suppression and favorable renal and bone safety","volume":"119","author":"Chan","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib253","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jhep.2016.05.014","article-title":"Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients","volume":"65","author":"Boyd","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib254","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","article-title":"Covalently closed circular DNA: the ultimate therapeutic target for curing HBV infections","volume":"75","author":"Martinez","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib255","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jhep.2021.04.051","article-title":"Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load","volume":"75","author":"Meier","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib256","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2024.06.037","article-title":"Hepatitis B virus DNA integration: implications for diagnostics, therapy, and outcome","author":"Zoulim","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib257","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib258","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib259","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2007.08.025","article-title":"Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B","volume":"133","author":"Gish","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib260","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2017.51","article-title":"Seven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels","volume":"8","author":"Lam","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib261","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00535-018-1502-y","article-title":"Long-term outcome of entecavir treatment of nucleos(t)ide analogue-na\u00efve chronic hepatitis B patients in Japan","volume":"54","author":"Suzuki","year":"2019","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib262","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib263","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib264","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib265","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib266","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","article-title":"Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection","volume":"60","author":"Buti","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2025.03.018_bib267","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/liv.14155","article-title":"Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection","volume":"39","author":"Marcellin","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib268","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cgh.2010.11.040","article-title":"Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B","volume":"9","author":"Schiff","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib269","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105782","article-title":"Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy","volume":"221","author":"Zhao","year":"2024","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhep.2025.03.018_bib270","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib271","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon Alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib272","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3851\/IMP2319","article-title":"Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir","volume":"17","author":"Sonneveld","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib273","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2217\/cer-2020-0068","article-title":"A comparative network meta-analysis of standard of care treatments in treatment-na\u00efve chronic hepatitis B patients","volume":"9","author":"Sbarigia","year":"2020","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.jhep.2025.03.018_bib274","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.52.3.420","article-title":"Durability of HBeAG seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase","volume":"52","author":"Van Nunen","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.03.018_bib275","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00535-009-0024-z","article-title":"Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection","volume":"44","author":"Miyake","year":"2009","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib276","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2893.2009.01070.x","article-title":"Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis","volume":"16","author":"Yang","year":"2009","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.03.018_bib277","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1365-2036.2008.03816.x","article-title":"Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma","volume":"28","author":"Sung","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib278","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0168-8278(01)00005-8","article-title":"Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach","volume":"34","author":"Camm\u00e0","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib279","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/infdis\/jiv547","article-title":"Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B","volume":"213","author":"Liang","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib280","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101758","article-title":"Comparison of Interferon-\u03b1-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B","volume":"46","author":"Mao","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib281","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib282","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.20760","article-title":"Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine","volume":"42","author":"Papatheodoridis","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib283","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/gutjnl-2012-302024","article-title":"Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis","volume":"62","author":"Zoutendijk","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.03.018_bib284","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib285","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jhep.2010.01.012","article-title":"Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues","volume":"52","author":"Reijnders","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib286","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib287","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1053\/j.gastro.2006.04.007","article-title":"Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B","volume":"130","author":"Sherman","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib288","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/hep.22323","article-title":"Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks","volume":"48","author":"Sherman","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib289","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/hep.26686","article-title":"No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B","volume":"59","author":"Kitrinos","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib290","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jhep.2017.03.027","article-title":"Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy","volume":"67","author":"Shirvani-Dastgerdi","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib291","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jhep.2019.02.006","article-title":"Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients","volume":"70","author":"Park","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib292","doi-asserted-by":"crossref","first-page":"986","DOI":"10.5246\/jcps.2021.12.085","article-title":"Comparison of the efficacy and adherence of generic and brand-name entecavirs in chronic hepatitis B patients: a multicenter cohort study","volume":"30","author":"Xie","year":"2021","journal-title":"J Chin Pharm Sci"},{"key":"10.1016\/j.jhep.2025.03.018_bib293","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.2147\/DDDT.S149199","article-title":"Baracle\u00ae vs Baraclude\u00ae for 48 weeks in patients with treatment-na\u00efve chronic hepatitis B: a comparison of efficacy and safety","volume":"11","author":"Kim","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib294","article-title":"Comparative effectiveness of entecavir vs tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B: a systematic review and meta-analysis","author":"Dave","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib295","article-title":"Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis","author":"Choi","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib296","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jhep.2022.12.007","article-title":"Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: individual patient data meta-analysis","volume":"78","author":"Choi","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib297","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S2468-1253(20)30249-1","article-title":"Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib298","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2020.06.011","article-title":"Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B","volume":"73","author":"Papatheodoridis","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib299","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/hep.24318","article-title":"Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice","volume":"53","author":"Hongthanakorn","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib300","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/hep4.1247","article-title":"Adherence to nucleos(t)ide analogue therapies for chronic hepatitis B infection: a systematic review and meta-analysis","volume":"2","author":"Ford","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.03.018_bib301","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"issue":"24","key":"10.1016\/j.jhep.2025.03.018_bib302","article-title":"Stopping nucleos(t)ide analogues in chronic hepatitis B using HBsAg thresholds: a meta-analysis and meta-regression","volume":"S1542\u20133565","author":"Lim","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib303","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/apt.13659","article-title":"Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients","volume":"44","author":"Lampertico","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib304","article-title":"Tenofovir-induced renal dysfunction among HIV-infected patients: a systematic review","volume":"15","author":"Shivakumar","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jhep.2025.03.018_bib305","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1365-2036.2012.05093.x","article-title":"Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B","volume":"35","author":"Gara","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib306","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/apc.2007.0052","article-title":"Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system","volume":"22","author":"Gupta","year":"2008","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.jhep.2025.03.018_bib307","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jcv.2014.09.016","article-title":"Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal","volume":"61","author":"Vigan\u00f2","year":"2014","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jhep.2025.03.018_bib308","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jhep.2017.08.020","article-title":"Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance","volume":"68","author":"Grossi","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib309","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/hep.25818","article-title":"Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B","volume":"56","author":"Murray","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib310","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/jac\/dku502","article-title":"Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study","volume":"70","author":"Maggi","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jhep.2025.03.018_bib311","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/infdis\/jiu471","article-title":"Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?","volume":"211","author":"Gill","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib312","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jhep.2023.12.001","article-title":"Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B","volume":"80","author":"Yip","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib313","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib314","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jhep.2019.02.021","article-title":"Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: a 5-year clinical trial","volume":"71","author":"Lim","year":"2019","journal-title":"J Hepatol"},{"issue":"18","key":"10.1016\/j.jhep.2025.03.018_bib315","first-page":"30633","article-title":"Improved bone safety of tenofovir alafenamide compared to tenofovir disoproxil fumarate over 2 Years in patients with chronic HBV infection","volume":"S1542\u20133565","author":"Seto","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib316","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/jvh.13053","article-title":"Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide","volume":"26","author":"Fong","year":"2019","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.03.018_bib317","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/apt.17716","article-title":"Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: a nationwide claims study in South Korea","volume":"58","author":"Kim","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib318","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3350\/cmh.2014.20.3.267","article-title":"Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir","volume":"20","author":"Ze","year":"2014","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib319","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26358","article-title":"Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta-analysis","volume":"27","author":"Yoo","year":"2024","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.jhep.2025.03.018_bib320","article-title":"Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate","volume":"14","author":"Lin","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2025.03.018_bib321","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s12072-023-10528-7","article-title":"Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis","volume":"17","author":"Hwang","year":"2023","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib322","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab621","article-title":"Lipid changes after switch from TDF to TAF in the OPERA cohort: LDL cholesterol and triglycerides","volume":"9","author":"Mallon","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib323","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101412","article-title":"Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysis","volume":"48","author":"Kanters","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jhep.2025.03.018_bib324","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1177\/08971900221105042","article-title":"Successful treatment of tenofovir alafenamide-induced lactic acidosis: a case report","volume":"36","author":"Arnouk","year":"2023","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.jhep.2025.03.018_bib325","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.23346","article-title":"Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function","volume":"50","author":"Lange","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib326","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1665-2681(19)30776-8","article-title":"The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis","volume":"14","author":"Zhang","year":"2015","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib327","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/ajg.2017.93","article-title":"Improvement of liver fibrosis after long-term antiviral therapy assessed by fibroscan in chronic hepatitis B patients with advanced fibrosis","volume":"112","author":"Chon","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib328","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/liv.12377","article-title":"Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir","volume":"34","author":"Kim","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib329","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/liv.13583","article-title":"Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B","volume":"38","author":"Jeon","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib330","doi-asserted-by":"crossref","first-page":"113213","DOI":"10.18632\/oncotarget.22375","article-title":"Validation of risk prediction models for the development of HBV-related HCC: a retrospective multi-center 10-year follow-up cohort study","volume":"8","author":"Seo","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2025.03.018_bib331","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/hep.28115","article-title":"Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy","volume":"62","author":"Jung","year":"2015","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2025.03.018_bib332","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/liv.12393","article-title":"Hepatitis B: are non-invasive markers of liver fibrosis reliable?","volume":"34","author":"Castera","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib333","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.14309\/ajg.0000000000001239","article-title":"Unreliable estimation of fibrosis regression during treatment by liver stiffness measurement in patients with chronic hepatitis B","volume":"116","author":"Ji","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib334","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/hep.28916","article-title":"Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment","volume":"66","author":"Kim","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib335","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1016\/j.cgh.2020.03.001","article-title":"Persistent low level of hepatitis B virus promotes fibrosis progression during therapy","volume":"18","author":"Sun","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib336","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s12072-020-10079-1","article-title":"Hepatitis B virus X gene mutants emerge during antiviral therapy and increase cccDNA levels to compensate for replication suppression","volume":"14","author":"Lin","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib337","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/s41395-018-0093-9","article-title":"Medication nonadherence increases hepatocellular carcinoma, cirrhotic complications, and mortality in chronic hepatitis B patients treated with entecavir","volume":"113","author":"Shin","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib338","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3350\/cmh.2020.0012","article-title":"Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir","volume":"26","author":"Lee","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib339","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3851\/IMP3087","article-title":"Factors associated with HBV virological breakthrough","volume":"22","author":"Sheppard-Law","year":"2017","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib340","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.dld.2015.03.024","article-title":"Real life adherence of chronic hepatitis B patients to entecavir treatment","volume":"47","author":"van Vlerken","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib341","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.xphs.2016.12.003","article-title":"Development of a novel formulation that improves preclinical bioavailability of tenofovir disoproxil fumarate","volume":"106","author":"Watkins","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jhep.2025.03.018_bib342","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s12072-016-9737-2","article-title":"Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure","volume":"10","author":"Zoulim","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib343","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib344","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib345","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/jvh.12738","article-title":"HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up","volume":"24","author":"Stelma","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.03.018_bib346","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/hep4.1436","article-title":"Durability of hepatitis B surface antigen loss with nucleotide analogue and peginterferon therapy in patients with chronic hepatitis B","volume":"4","author":"Lok","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.03.018_bib347","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1017\/S0950268816001217","article-title":"Time to seroconversion of HBsAg to anti-HBs in individuals who lost HBsAg during follow-up","volume":"144","author":"Roushan","year":"2016","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jhep.2025.03.018_bib348","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/infdis\/jis569","article-title":"Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation","volume":"206","author":"Tseng","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib349","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/hep.28438","article-title":"Discontinuation of oral antivirals in chronic hepatitis B: a systematic review","volume":"63","author":"Papatheodoridis","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib350","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijid.2015.10.019","article-title":"Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients","volume":"43","author":"wang","year":"2016","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib351","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/MCG.0b013e31825ceed9","article-title":"High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy","volume":"46","author":"Chaung","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib352","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1038\/ajg.2009.200","article-title":"The duration of lamivudine therapy for chronic hepatitis b: cessation vs. continuation of treatment after HBeAg seroconversion","volume":"104","author":"Fung","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib353","first-page":"2332","article-title":"Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study","volume":"68","author":"Dai","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jhep.2025.03.018_bib354","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1055\/a-1498-2512","article-title":"S3-Leitlinie der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion \u2013 (AWMF-Register-Nr. 021-11)","volume":"59","author":"Cornberg","year":"2021","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib355","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/apt.13272","article-title":"Systematic review: Cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B","volume":"42","author":"Chang","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib356","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/apt.13150","article-title":"Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B","volume":"41","author":"Chi","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib357","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jhep.2022.12.018","article-title":"A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B","volume":"78","author":"van B\u00f6mmel","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib358","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/infdis\/jiw412","article-title":"Viral and host responses after stopping long-term Nucleos(t)ide analogue therapy in HBeAg-negative chronic Hepatitis B","volume":"214","author":"H\u00f6ner Zu Siederdissen","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib359","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib360","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib361","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3851\/IMP3256","article-title":"Daring-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B","volume":"23","author":"Papatheodoridis","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib362","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib363","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/infdis\/jiy097","article-title":"Increased NK cell function after cessation of long-term nucleos(t)ide analogue treatment in chronic hepatitis B is associated with liver damage and HBsAg loss","volume":"217","author":"Zimmer","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib364","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2018.05.004","article-title":"Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B","volume":"69","author":"Rinker","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib365","article-title":"Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: a systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.018_bib366","doi-asserted-by":"crossref","DOI":"10.1111\/apt.18147","article-title":"Clinical trial: an open-label, randomised trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B","author":"Johannessen","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib367","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.cgh.2022.07.005","article-title":"Differential relapse patterns after discontinuation of entecavir vs tenofovir disoproxil fumarate in chronic hepatitis B","volume":"21","author":"Choi","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib368","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/infdis\/jiy350","article-title":"Contrasting timing of virological relapse after discontinuation of tenofovir or entecavir in Hepatitis B e antigen-negative patients","volume":"218","author":"H\u00f6ner zu Siederdissen","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib369","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/infdis\/jix690","article-title":"Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy","volume":"217","author":"Su","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib370","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000003324","article-title":"Higher relapse rate in HBeAg-negative patients after cessation of tenofovir alafenamide compared with entecavir or tenofovir disoproxil fumarate","author":"Fang","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib371","article-title":"Predictors of hepatic flares after nucleos(t)ide analogue cessation \u2013 results of a global cohort study (RETRACT-B study)","author":"Dongelmans","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib372","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.cgh.2022.08.021","article-title":"The Role of Off-Therapy Viral Kinetics in the Timing and Severity of Flares in Hepatitis B e Antigen-Negative Patients","volume":"21","author":"Liu","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib373","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1111\/jgh.15966","article-title":"A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off-therapy relapse: an observational study","volume":"37","author":"Peng","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib374","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.14309\/ajg.0000000000002203","article-title":"Incidence of hepatic decompensation after nucleos(t)ide analog withdrawal: results from a large, international, multiethnic cohort of patients with chronic hepatitis B (RETRACT-B study)","volume":"118","author":"Hirode","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib375","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2022.03.006","article-title":"A case of HBV-induced liver failure in the REEF-2 phase II trial: implications for finite treatment strategies in HBV \u201ccure.\u201d","volume":"77","author":"Agarwal","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib376","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib377","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/apt.13409","article-title":"Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis","volume":"42","author":"Chen","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib378","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s00535-015-1153-1","article-title":"Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients","volume":"51","author":"Jung","year":"2016","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib379","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/HEP.0000000000000575","article-title":"Hepatocellular carcinoma reduced, HBsAg loss increased, and survival improved after finite therapy in hepatitis B patients with cirrhosis","volume":"79","author":"Jeng","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib380","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/liv.15128","article-title":"Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: a multicentre cohort study","volume":"42","author":"Papatheodoridi","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib381","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/apt.17880","article-title":"Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals","volume":"59","author":"Liu","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib382","article-title":"Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels: a multicenter study (CREATE)","author":"Sonneveld","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib383","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/jac\/dkac409","article-title":"Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation","volume":"78","author":"Tseng","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jhep.2025.03.018_bib384","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12876-023-02852-x","article-title":"Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation","volume":"23","author":"Xie","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib385","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/hep.31026","article-title":"Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy","volume":"72","author":"Carey","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib386","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12072-021-10159-w","article-title":"Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation","volume":"15","author":"Kuo","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib387","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/apt.15058","article-title":"Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk","volume":"49","author":"Hsu","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib388","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/infdis\/jiaa136","article-title":"Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B","volume":"222","author":"Fan","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib389","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jmii.2022.06.002","article-title":"End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients","volume":"56","author":"Brakenhoff","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jhep.2025.03.018_bib390","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1111\/liv.15433","article-title":"Low anti-HBc levels are associated with lower risk of virological relapse after nucleos(t)ide analogue cessation in HBe antigen-negative patients","volume":"42","author":"Ohlendorf","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib391","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cgh.2018.05.047","article-title":"Serum level of antibodies against hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos(t)ide analogue therapy","volume":"17","author":"Chi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib392","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000188","article-title":"Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants","volume":"7","author":"Thompson","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.03.018_bib393","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hep4.1626","article-title":"Pilot study using machine learning to identify immune profiles for the prediction of early virological relapse after stopping nucleos(t)ide analogues in HBeAg-negative CHB","volume":"5","author":"W\u00fcbbolding","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.03.018_bib394","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1172\/JCI92812","article-title":"Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation","volume":"128","author":"Rivino","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2025.03.018_bib395","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.jhep.2020.11.043","article-title":"Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients","volume":"74","author":"Garc\u00eda-L\u00f3pez","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib396","article-title":"Utility of novel viral and immune markers in predicting HBV treatment endpoints: a systematic review of treatment discontinuation studies","volume":"5","author":"Zeng","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.018_bib397","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/jvh.13528","article-title":"The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients","volume":"28","author":"Huang","year":"2021","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.03.018_bib398","article-title":"Clinical utility of SCALE-B to predict hepatitis B virus relapse, hepatitis B surface antigen loss after antiviral cessation in Asian patients after 2-year follow-up","volume":"9","author":"Kaewdech","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jhep.2025.03.018_bib399","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/jvh.13211","article-title":"Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B","volume":"27","author":"Papatheodoridi","year":"2020","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.03.018_bib400","article-title":"Limited value of HBV-RNA for relapse prediction after nucleos(t)ide analogue withdrawal in HBeAg-negative hepatitis B patients","author":"Ohlendorf","year":"2024","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.03.018_bib401","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s00535-021-01812-0","article-title":"HBeAg-positive patients with HBsAg < 100 IU\/ml and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation","volume":"56","author":"Xie","year":"2021","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib402","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.cgh.2019.07.046","article-title":"Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of Nucles(t)ide analogue therapy","volume":"18","author":"Fan","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib403","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jhep.2022.01.007","article-title":"Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels","volume":"76","author":"Sonneveld","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib404","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","article-title":"Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa","volume":"137","author":"Buster","year":"2009","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2025.03.018_bib405","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/liv.13635","article-title":"Treatment of hepatitis B: is there still a role for interferon?","volume":"38","author":"Vigan\u00f2","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib406","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/apt.14862","article-title":"A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B","volume":"48","author":"Chan","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib407","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3851\/IMP3251","article-title":"An easy-to-use baseline scoring system to predict response to peginterferon alfa-2a in patients with chronic hepatitis B in resource-limited settings","volume":"23","author":"Lampertico","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib408","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.24555","article-title":"Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib409","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/gutjnl-2011-301430","article-title":"Randomised study comparing 48 and 96 weeks peginterferon \u03b1-2a therapy in genotype D HBeAg-negative chronic hepatitis B","volume":"62","author":"Lampertico","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.03.018_bib410","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.bpg.2008.11.007","article-title":"Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues","volume":"22","author":"Buster","year":"2008","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib411","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.03.018_bib412","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/hep.26436","article-title":"Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels","volume":"58","author":"Sonneveld","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib413","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2011.12.007","article-title":"Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a","volume":"56","author":"Rijckborst","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib414","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3851\/IMP3367","article-title":"Hepatitis B core-related antigen levels predict pegylated interferon-\u03b1 therapy response in HBeAg-positive chronic hepatitis B","volume":"25","author":"Beudeker","year":"2020","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib415","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jhep.2022.01.021","article-title":"End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB","volume":"77","author":"Huang","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib416","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2017.07.016","article-title":"Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy","volume":"24","author":"Chuaypen","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhep.2025.03.018_bib417","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/jvh.12341","article-title":"Combination therapy of interferon and nucleotide\/nucleoside analogues for chronic hepatitis B","volume":"21","author":"Wong","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.03.018_bib418","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon \u03b1-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib419","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/apt.14629","article-title":"Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance","volume":"47","author":"Qiu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib420","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S2468-1253(16)30189-3","volume":"2","author":"Bourli\u00e8re","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib421","article-title":"Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2025.03.018_bib422","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jhep.2024.07.019","article-title":"PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: a randomized-controlled trial","volume":"82","author":"Li","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib423","first-page":"441","article-title":"Platelet and white blood cell counts during therapy with different types of alpha interferon in patients with chronic viral hepatitis","volume":"29","author":"Colombatto","year":"1997","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib424","first-page":"104","article-title":"A meta-analysis of patients with chronic hepatitis C treated with interferon-alpha to determine the risk of autoimmune thyroiditis","volume":"41","author":"Andrade","year":"2011","journal-title":"Acta Gastroenterologica Latinoamericana"},{"key":"10.1016\/j.jhep.2025.03.018_bib425","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcv.2008.02.007","article-title":"ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B","volume":"42","author":"ter Borg","year":"2008","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jhep.2025.03.018_bib426","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.psym.2013.06.015","article-title":"Antidepressant pretreatment for the prevention of interferon alfa-associated depression: a systematic review and meta-analysis","volume":"55","author":"Sarkar","year":"2014","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jhep.2025.03.018_bib427","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib428","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib429","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jhep.2022.01.023","article-title":"HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis","volume":"77","author":"Singal","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib430","doi-asserted-by":"crossref","first-page":"261","DOI":"10.7326\/M14-0558","article-title":"Screening for hepatocellular carcinoma in chronic liver disease: a systematic review","volume":"161","author":"Kansagara","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib431","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","article-title":"Randomized controlled trial of screening for hepatocellular carcinoma","volume":"130","author":"Zhang","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jhep.2025.03.018_bib432","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib433","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/hep.29320","article-title":"The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B","volume":"66","author":"Papatheodoridis","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib434","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1016\/j.cgh.2021.02.040","article-title":"Hepatocellular carcinoma prediction models in chronic hepatitis B: a systematic review of 14 models and external validation","volume":"19","author":"Wu","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib435","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12985-023-02145-5","article-title":"HCC prediction models in chronic hepatitis B patients receiving entecavir or tenofovir: a systematic review and meta-analysis","volume":"20","author":"Xu","year":"2023","journal-title":"Virol J"},{"key":"10.1016\/j.jhep.2025.03.018_bib436","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/liv.14334","article-title":"Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B","volume":"40","author":"Voulgaris","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib437","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1136\/gutjnl-2014-309099","article-title":"The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection","volume":"65","author":"Abu-Amara","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.03.018_bib438","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jhep.2020.01.007","article-title":"Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B","volume":"72","author":"Papatheodoridis","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib439","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.14309\/ajg.0000000000001865","article-title":"Comparative performance of 14 HCC prediction models in CHB: a dynamic validation at serial on-treatment Timepoints","volume":"117","author":"Wu","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib440","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1016\/j.cgh.2023.02.004","article-title":"Diabetes mellitus impacts on the performance of hepatocellular carcinoma risk scores in chronic hepatitis B patients","volume":"21","author":"Yip","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib441","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib442","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2147\/JHC.S372571","article-title":"Incidence of hepatocellular carcinoma and decompensated liver cirrhosis and prognostic accuracy of the PAGE-B HCC risk score in a low endemic hepatitis B virus infected population","volume":"9","author":"Bollerup","year":"2022","journal-title":"J Hepatocellular Carcinoma"},{"key":"10.1016\/j.jhep.2025.03.018_bib443","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jhep.2022.12.029","article-title":"External validation of the PAGE-B score for HCC risk prediction in people living with HIV\/HBV coinfection","volume":"78","author":"Surial","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib444","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2019.12.005","article-title":"Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B","volume":"72","author":"Yip","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib445","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/1751-2980.13172","article-title":"CAGE-B and SAGE-B models better predict the hepatitis B virus-related hepatocellular carcinoma after 5-year entecavir treatment than PAGE-B","volume":"24","author":"Chon","year":"2023","journal-title":"J Dig Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib446","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jhep.2018.07.018","article-title":"Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy","volume":"69","author":"Kim","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib447","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004311","article-title":"Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: a meta-analysis","volume":"95","author":"Coppola","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhep.2025.03.018_bib448","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jhep.2022.03.032","article-title":"A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance","volume":"77","author":"Yang","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib449","article-title":"Incidence of hepatocellular carcinoma in a community-based Taiwanese population without chronic HBV\/HCV infection","volume":"4","author":"Wu","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.018_bib450","first-page":"401","article-title":"Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis","volume":"70","author":"Nathani","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.03.018_bib451","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.14680","article-title":"Optimal intervals of ultrasonography screening for early diagnosis of hepatocellular carcinoma in Taiwan","volume":"4","author":"Kuo","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhep.2025.03.018_bib452","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/ajg.2012.445","article-title":"Hepatocellular carcinoma surveillance at 4-vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community","volume":"108","author":"Wang","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib453","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.dld.2021.08.025","article-title":"Surveillance for hepatocellular carcinoma with a 3-months interval in \u201cextremely high-risk\u201d patients does not further improve survival","volume":"54","author":"Pelizzaro","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib454","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/hep.24545","article-title":"Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities","volume":"54","author":"Trinchet","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib455","article-title":"Diagnosis and management of chronic hepatitis B in children, young people, and adults: summary of NICE guidance","volume":"346","author":"Sarri","year":"2013","journal-title":"BMJ (Clinical Research Ed)"},{"key":"10.1016\/j.jhep.2025.03.018_bib456","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2036.2009.04014.x","article-title":"Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis","volume":"30","author":"Singal","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib457","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1159\/000506834","article-title":"A comparison of Biannual two-phase low-dose liver CT and US for HCC surveillance in a group at high risk of HCC development","volume":"9","author":"Yoon","year":"2020","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2025.03.018_bib458","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/liv.15110","article-title":"Abbreviated magnetic resonance imaging vs ultrasound for surveillance of hepatocellular carcinoma in high-risk patients","volume":"42","author":"Park","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib459","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1055\/a-2189-6353","article-title":"S3-Leitlinie \u201cDiagnostik und Therapie des Hepatozellul\u00e4ren Karzinoms\u201c \u2013 Langversion 4.0","volume":"62","author":"Bitzer","year":"2024","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib460","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.3390\/ijms24054286","article-title":"Updating the clinical application of blood biomarkers and their algorithms in the diagnosis and surveillance of hepatocellular carcinoma: a critical review","volume":"24","author":"Shahini","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2025.03.018_bib461","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.14309\/ajg.0000000000000715","article-title":"Cost-effectiveness of hepatocellular carcinoma surveillance: an assessment of benefits and harms","volume":"115","author":"Parikh","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib462","article-title":"A phase 3 biomarker validation of GALAD for the detection of hepatocellular carcinoma in cirrhosis","author":"Marsh","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib463","article-title":"Comparative evaluation of multimarker algorithms for early-stage HCC detection in multicenter prospective studies","author":"Hou","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.018_bib464","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hep.21486","article-title":"A randomized controlled trial of lamivudine to treat acute hepatitis B","volume":"45","author":"Kumar","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib465","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10620-009-1060-5","article-title":"The study of efficacy of lamivudine in patients with severe acute hepatitis B","volume":"55","author":"Yu","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2025.03.018_bib466","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/jvh.12210","article-title":"Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial","volume":"21","author":"Wiegand","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.03.018_bib467","article-title":"Pharmacological interventions for acute hepatitis B infection: an attempted network meta-analysis","volume":"2017","author":"Mantzoukis","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhep.2025.03.018_bib468","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2893.2005.00695.x","article-title":"Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience","volume":"13","author":"Tillmann","year":"2006","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.03.018_bib469","first-page":"1306","article-title":"Therapie der akuten fulminanten Hepatitis B mit Nucleos(t)id-Analogen ist sicher und f\u00fchrt nicht zur Chronifizierung der Hepatitis B","volume":"54","author":"Jochum","year":"2016","journal-title":"Z Gastroenterologie"},{"key":"10.1016\/j.jhep.2025.03.018_bib470","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1478-3231.2011.02450.x","article-title":"Lamivudine treatment is associated with improved survival in fulminant hepatitis B","volume":"31","author":"Yu","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib471","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.reprotox.2011.11.003","article-title":"A systematic review of the fetal safety of interferon alpha","volume":"33","author":"Yazdani Brojeni","year":"2012","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.jhep.2025.03.018_bib472","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/hep.28302","article-title":"Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis","volume":"63","author":"Brown","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib473","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-018-0847-2","article-title":"Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: a meta-analysis based on 6 studies from China and 3 studies from other countries","volume":"18","author":"Li","year":"2018","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib474","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jvh.12785","article-title":"Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy: long-term follow-up","volume":"24","author":"Shang","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.03.018_bib475","doi-asserted-by":"crossref","first-page":"e3324","DOI":"10.1093\/cid\/ciaa1939","article-title":"Tenofovir alafenamide to prevent perinatal hepatitis B transmission: a multicenter, prospective, observational study","volume":"73","author":"Zeng","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib476","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/apt.16043","article-title":"Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study","volume":"52","author":"Ding","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib477","article-title":"Safety and efficacy of tenofovir alafenamide fumarate in early-middle pregnancy for mothers with chronic hepatitis B","volume":"8","author":"Chen","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jhep.2025.03.018_bib478","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae288","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for preventing vertical transmission in chronic hepatitis B mothers: a systematic review and meta-analysis","author":"Pan","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib479","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2013.02.015","article-title":"Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention","volume":"59","author":"Wen","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib480","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.cgh.2011.10.041","article-title":"An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus","volume":"10","author":"Pan","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib481","article-title":"Efficacy of tenofovir in preventing perinatal transmission of HBV infection in pregnant women with high viral loads","volume":"8","author":"Lin","year":"2018","journal-title":"Scientific Rep"},{"key":"10.1016\/j.jhep.2025.03.018_bib482","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","article-title":"Tenofovir to prevent hepatitis B transmission in mothers with high viral load","volume":"374","author":"Pan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib483","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa1708131","article-title":"Tenofovir versus placebo to prevent perinatal transmission of hepatitis B","volume":"378","author":"Jourdain","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib484","article-title":"Expected 8-week prenatal vs 12-week perinatal tenofovir alafenamide prophylaxis to prevent mother-to-child transmission of hepatitis B virus: a multicenter, prospective, open-label, randomized controlled trial","author":"Zeng","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib485","article-title":"Real-world clinical data-driven modelling on the initiation time of antiviral prophylaxis among pregnant women with chronic hepatitis B infection","author":"Shen","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib486","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jama.2024.22952","article-title":"Tenofovir and hepatitis B virus transmission during pregnancy: a randomized clinical trial","volume":"333","author":"Pan","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2025.03.018_bib487","first-page":"1425","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)","volume":"11","author":"You","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib488","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S1473-3099(20)30586-7","article-title":"Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis","volume":"21","author":"Funk","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib489","article-title":"Immediate postpartum cessation of tenofovir did not increase risk of virological or clinical relapse in highly viremic pregnant mothers with chronic hepatitis B infection","volume":"6","author":"Chen","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.018_bib490","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.14309\/ajg.0000000000000221","article-title":"Total alanine aminotransferase (ALT) flares in pregnant North American women with chronic hepatitis B infection: results from a prospective observational study","volume":"114","author":"Bzowej","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib491","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/j.cgh.2018.10.007","article-title":"Management algorithm for interrupting mother-to-child transmission of hepatitis B virus","volume":"17","author":"Hou","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib492","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/liv.15372","article-title":"Predicting hepatitis B e Antigen seroconversion after pregnancy-The SydPregScore","volume":"43","author":"Thilakanathan","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib493","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1136\/gutjnl-2014-308211","article-title":"Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B","volume":"64","author":"Giles","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.03.018_bib494","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s12072-008-9063-4","article-title":"Chronic hepatitis B virus (HBV) infection in pregnancy","volume":"2","author":"Tan","year":"2008","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib495","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/cid\/ciu798","article-title":"Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence","volume":"60","author":"Ehrhardt","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib496","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijid.2019.07.023","article-title":"Guides concerning tenofovir exposure via breastfeeding: a comparison of drug dosages by developmental stage","volume":"87","author":"Hu","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib497","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106726","article-title":"Low levels of tenofovir in breast milk support breastfeeding in HBV-infected mothers treated with tenofovir disoproxil fumarate","volume":"61","author":"Li","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jhep.2025.03.018_bib498","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s12072-021-10235-1","article-title":"Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load","volume":"15","author":"Li","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib499","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/QAD.0000000000001313","article-title":"Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding","volume":"31","author":"Mofenson","year":"2017","journal-title":"Aids"},{"key":"10.1016\/j.jhep.2025.03.018_bib500","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/14740338.2017.1338271","article-title":"Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women","volume":"16","author":"Mugwanya","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jhep.2025.03.018_bib501","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/apt.15064","article-title":"Real-world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load","volume":"49","author":"Wang","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib502","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/archpediatrics.2011.72","article-title":"Breastfeeding of newborns by mothers carrying hepatitis B virus: a meta-analysis and systematic review","volume":"165","author":"Shi","year":"2011","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib503","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/jvh.13314","article-title":"The role of caesarean section and nonbreastfeeding in preventing mother-to-child transmission of hepatitis B virus in HBsAg-and HBeAg-positive mothers: results from a prospective cohort study and a meta-analysis","volume":"27","author":"Pan","year":"2020","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.03.018_bib504","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/jvh.13455","article-title":"Caesarean section or non-breastfeeding for prevention of MTCT-beware of sending the wrong message","volume":"28","author":"Levy","year":"2021","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.03.018_bib505","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12884-017-1487-1","article-title":"Cesarean section to prevent mother-to-child transmission of hepatitis B virus in China: a meta-analysis","volume":"17","author":"Yang","year":"2017","journal-title":"BMC Pregnancy and Childbirth"},{"key":"10.1016\/j.jhep.2025.03.018_bib506","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.midw.2019.03.024","article-title":"Vaginal delivery and HBV mother to child transmission risk after immunoprophylaxis: a systematic review and a meta-analysis","volume":"74","author":"Chen","year":"2019","journal-title":"Midwifery"},{"key":"10.1016\/j.jhep.2025.03.018_bib507","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.cgh.2013.04.026","article-title":"Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis b surface antigen-positive women to their infants","volume":"11","author":"Pan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib508","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.27723","article-title":"Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis","volume":"61","author":"Jang","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib509","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2012.02.033","article-title":"Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy","volume":"57","author":"Peng","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib510","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jhep.2022.07.037","article-title":"Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis","volume":"77","author":"Wang","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib511","article-title":"Baveno VII criteria for recompensation predict transplant-free survival in patients with hepatitis B-related decompensated cirrhosis","volume":"5","author":"Hui","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.018_bib512","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3390\/v15051037","article-title":"The role of antiviral prophylaxis in preventing HBV and HDV recurrence in the setting of liver transplantation","volume":"15","author":"Battistella","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.jhep.2025.03.018_bib513","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12876-023-03024-7","article-title":"Efficacy and safety of tenofovir disoproxil fumarate versus entecavir in the treatment of acute-on-chronic liver failure with hepatitis B: a systematic review and meta-analysis","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib514","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1186\/s12879-021-06237-x","article-title":"Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B","volume":"21","author":"Li","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib515","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1185492","article-title":"Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-on-chronic liver failure: real-world study","volume":"14","author":"Peng","year":"2023","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jhep.2025.03.018_bib516","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007133","article-title":"Fatal lactic acidosis in hepatitis B virus-associated decompensated cirrhosis treated with tenofovir: a case report","volume":"96","author":"Jung","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhep.2025.03.018_bib517","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3851\/IMP3375","article-title":"Viral suppression is comparable with 0.5 mg and 1.0 mg daily doses of entecavir in treatment-naive HBV-related decompensated cirrhosis","volume":"25","author":"Goel","year":"2020","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib518","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S2468-1253(24)00096-7","article-title":"Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study","volume":"9","author":"Janssen","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib519","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/bmj.306.6870.107","article-title":"Fatal hepatic decompensation associated with interferon alfa. European concerted action on viral hepatitis (Eurohep)","volume":"306","author":"Janssen","year":"1993","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2025.03.018_bib520","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/jgh.16132","article-title":"The clinical effect of antiviral therapy in patients with hepatitis B virus-related decompensated cirrhosis and undetectable DNA","volume":"38","author":"Lee","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib521","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/SLA.0000000000002727","article-title":"Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial","volume":"268","author":"Huang","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2025.03.018_bib522","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/apt.14801","article-title":"Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience","volume":"48","author":"Chen","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib523","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7075935","article-title":"Efficacy of Nucleot(s)ide analogs therapy in patients with unresectable HBV-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"2017","author":"He","year":"2017","journal-title":"Dis Markers"},{"key":"10.1016\/j.jhep.2025.03.018_bib524","article-title":"Evaluation of antiviral therapy performed after curative therapy in patients with HBV-related hepatocellular carcinoma: an updated meta-analysis","volume":"2016","author":"Yuan","year":"2016","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib525","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.clinre.2014.12.003","article-title":"Efficacy of antiviral therapy with nucleotide\/nucleoside analogs after curative treatment for patients with hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"39","author":"Xia","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib526","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/SLA.0000000000000858","article-title":"Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma","volume":"261","author":"Huang","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2025.03.018_bib527","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1007\/s00268-014-2586-z","article-title":"Antiviral therapy decreases recurrence of hepatitis b virus-related hepatocellular carcinoma after curative resection: a meta-analysis","volume":"38","author":"Zhou","year":"2014","journal-title":"World J Surg"},{"key":"10.1016\/j.jhep.2025.03.018_bib528","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1200\/JCO.2012.48.5896","article-title":"Effect of antiviral treatment with nucleotide\/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study","volume":"31","author":"Yin","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.03.018_bib529","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1365-2036.2011.04634.x","article-title":"Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma","volume":"33","author":"Wong","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib530","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12885-023-10694-9","article-title":"TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma","volume":"23","author":"Lu","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhep.2025.03.018_bib531","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1097\/JS9.0000000000000554","article-title":"Tenofovir versus entecavir on the prognosis of hepatitis B-related hepatocellular carcinoma after surgical resection: a randomised controlled trial","volume":"109","author":"Linye","year":"2023","journal-title":"Int J Surg"},{"key":"10.1016\/j.jhep.2025.03.018_bib532","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/17474124.2023.2212161","article-title":"Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"17","author":"Liu","year":"2023","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib533","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13027-022-00478-4","article-title":"Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation","volume":"18","author":"Yang","year":"2023","journal-title":"Infect Agent Cancer"},{"key":"10.1016\/j.jhep.2025.03.018_bib534","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.31289","article-title":"Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection","volume":"73","author":"Choi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib535","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jvh.13766","article-title":"Tenofovir versus entecavir for tertiary prevention of hepatocellular carcinoma in chronic hepatitis B infection after curative therapy: a systematic review and meta-analysis","volume":"30","author":"Giri","year":"2023","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.03.018_bib536","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.cgh.2024.07.013","article-title":"Tenofovir is associated with a better prognosis than entecavir for hepatitis B virus-related hepatocellular carcinoma","volume":"23","author":"Chung","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib537","article-title":"Global burden of hepatitis B infection in people living with human immunodeficiency virus: a systematic review and meta-analysis","author":"Leumi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib538","series-title":"Deutsch-\u00f6sterreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion","volume":"vol. 128","year":"2003"},{"key":"10.1016\/j.jhep.2025.03.018_bib540","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/QAI.0000000000001069","article-title":"Brief report: efficacy and safety of switching to a single-tablet regimen of Elvitegravir\/Cobicistat\/emtricitabine\/tenofovir alafenamide in HIV-1\/Hepatitis B-coinfected adults","volume":"73","author":"Gallant","year":"2016","journal-title":"J Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.jhep.2025.03.018_bib541","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/QAI.0000000000003079","article-title":"Brief report: effect of antiretroviral switch from tenofovir disoproxil fumarate to tenofovir alafenamide on alanine aminotransferase, lipid profiles, and renal function in HIV\/HBV-coinfected individuals in a nationwide Canadian study","volume":"91","author":"Sarowar","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jhep.2025.03.018_bib542","article-title":"Week 96 results of switching from tenofovir disoproxil fumarate-based antiretroviral therapy to Coformulated Elvitegravir, Cobicistat, emtricitabine, and tenofovir alafenamide among HIV\/hepatitis B virus-coinfected patients","volume":"11","author":"Huang","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jhep.2025.03.018_bib543","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac451","article-title":"Hepatitis B-related hepatic flare during immune reconstitution syndrome after antiretroviral treatment initiation in an HBV surface antigen-positive patient with HIV: Viroimmunological and histological characterization","volume":"9","author":"Iannetta","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib544","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/infdis\/jiaa662","article-title":"Impact of immune reconstitution-induced hepatic flare on hepatitis B surface antigen loss in hepatitis B virus\/human immunodeficiency virus-1 coinfected patients","volume":"223","author":"Yoshikawa","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib545","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.31823","article-title":"A prospective study evaluating changes in histology, clinical and virologic outcomes in HBV-HIV Co-infected adults in North America","volume":"74","author":"Sterling","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib546","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jhep.2022.07.016","article-title":"Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension","volume":"77","author":"Degasperi","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib547","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/HEP.0000000000000847","article-title":"Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case series","volume":"80","author":"Dietz-Fricke","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib548","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70033","article-title":"Bulevirtide in chronic hepatitis D patients awaiting liver transplantation results from a French multicentric retrospective study","volume":"45","author":"Meszaros","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib549","article-title":"Treating hepatitis D with bulevirtide - real-world experience from 114 patients","volume":"5","author":"Dietz-Fricke","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.018_bib550","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0168-8278(03)00470-7","article-title":"Epidemiological and clinical burden of chronic hepatitis B virus\/hepatitis C virus infection. A multicenter Italian study","volume":"39","author":"Gaeta","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib551","first-page":"783","article-title":"Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections","volume":"104","author":"Liu","year":"2005","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jhep.2025.03.018_bib552","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0140-6736(06)69374-4","article-title":"Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study","volume":"368","author":"Amin","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.03.018_bib553","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/(SICI)1097-0215(19980130)75:3<347::AID-IJC4>3.0.CO;2-2","article-title":"A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma","volume":"75","author":"Donato","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhep.2025.03.018_bib554","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.bjc.6602333","article-title":"A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China","volume":"92","author":"Shi","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2025.03.018_bib555","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ijc.25321","article-title":"Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis","volume":"128","author":"Cho","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhep.2025.03.018_bib556","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/jmv.1890460316","article-title":"Long-term follow-up of hepatitis B virus and hepatitis C virus replicative levels in chronic hepatitis patients coinfected with both viruses","volume":"46","author":"Ohkawa","year":"1995","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2025.03.018_bib557","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/j.1572-0241.2002.05707.x","article-title":"Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection","volume":"97","author":"Squadrito","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib558","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/hep.20944","article-title":"Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus\/hepatitis C virus-coinfected patients","volume":"43","author":"Raimondo","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib559","doi-asserted-by":"crossref","first-page":"710.e1","DOI":"10.1016\/j.cmi.2015.03.003","article-title":"Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-\u03b3-induced protein 10 levels in HBV\/HCV-coinfected patients","volume":"21","author":"Wiegand","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhep.2025.03.018_bib560","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.gastro.2017.11.011","article-title":"Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV","volume":"154","author":"Liu","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib561","article-title":"Hepatitis B virus coinfection in patients treated for chronic hepatitis C: clinical characteristics, risk of reactivation with long-term follow-up, and effectiveness of antiviral therapy","volume":"134","author":"Zar\u0119bska-Michaluk","year":"2024","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib562","first-page":"1691","article-title":"An update on the treatment options for HBV\/HCV coinfection","volume":"18","author":"Sagnelli","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jhep.2025.03.018_bib563","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib564","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3109\/00365520903329585","article-title":"Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin","volume":"44","author":"Potthoff","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib565","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/infdis\/jiy648","article-title":"Pretreatment hepatitis B viral load predicts long-term hepatitis B response after anti-hepatitis C therapy in hepatitis B\/C dual-infected patients","volume":"219","author":"Yeh","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib566","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.gastro.2008.10.049","article-title":"Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses","volume":"136","author":"Liu","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib567","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/hep.29109","article-title":"Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis","volume":"66","author":"Chen","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib568","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","article-title":"Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis","volume":"3","author":"M\u00fccke","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib569","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/jvh.12784","article-title":"Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: data from a national US cohort","volume":"25","author":"Serper","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.03.018_bib570","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/14787210.2020.1782189","article-title":"Low risk of HBV reactivation in a large European cohort of HCV\/HBV coinfected patients treated with DAA","volume":"18","author":"Jaroszewicz","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib571","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.3390\/v14081812","article-title":"The predictive role of hepatitis B biomarkers on HBV reactivation following direct-acting antiviral therapy in HBV\/HCV coinfected patients","volume":"14","author":"Tseng","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.jhep.2025.03.018_bib572","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3390\/jpm12121957","article-title":"Direct-acting antivirals and the risk of hepatitis B reactivation in hepatitis B and C Co-infected patients: a systematic review and meta-analysis","volume":"12","author":"Oh","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib573","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jhep.2020.01.027","article-title":"Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV\/HCV co-infection","volume":"73","author":"Yeh","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib574","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.cgh.2021.11.032","article-title":"Entecavir prevents HBV reactivation during direct acting antivirals for HCV\/HBV dual infection: a randomized trial","volume":"20","author":"Cheng","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib575","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1007\/s10620-023-07916-2","article-title":"Low rate of hepatitis B reactivation among patients with chronic hepatitis C during direct acting antiviral therapy","volume":"68","author":"Majeed","year":"2023","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2025.03.018_bib576","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1002\/hep.22945","article-title":"Reactivation of hepatitis B","volume":"49","author":"Hoofnagle","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib577","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.jhep.2022.07.003","article-title":"Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: a systematic review, meta-analysis, and expert opinion","volume":"77","author":"Papatheodoridis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib578","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jvh.12402","article-title":"Hepatitis B reactivation in HBsAg-negative\/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis","volume":"22","author":"Mozessohn","year":"2015","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.03.018_bib579","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib580","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis b virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib581","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals","volume":"168","author":"Ali","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib582","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/jmv.24423","article-title":"High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin\u2019s lymphoma","volume":"88","author":"Cho","year":"2016","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2025.03.018_bib583","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1007\/s10620-023-08141-7","article-title":"Size matters! Anti-HBs titer and HBV reactivation during anti-TNF therapy","volume":"68","author":"Poola","year":"2023","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2025.03.018_bib584","first-page":"480","article-title":"Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review","volume":"31","author":"Cholongitas","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib585","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jhep.2019.08.023","article-title":"Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure","volume":"72","author":"Wong","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib586","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/apt.17155","article-title":"Meta-analysis: hepatitis B reactivation in patients receiving biological therapy","volume":"56","author":"El Jamaly","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib587","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S1473-3099(16)00118-3","article-title":"Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5)","volume":"16","author":"Mallet","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib588","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","article-title":"APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy","volume":"15","author":"Lau","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib589","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/hep.27716","article-title":"Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection","volume":"62","author":"Barone","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib590","article-title":"Risk of hepatitis B reactivation in HBsAg-\/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis","volume":"11","author":"Hong","year":"2023","journal-title":"A Meta-analysis Immun Inflamm Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib591","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s00432-022-04133-8","article-title":"Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis","volume":"149","author":"Ding","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jhep.2025.03.018_bib592","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib593","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12072-022-10450-4","article-title":"Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors","volume":"17","author":"Lei","year":"2023","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib594","doi-asserted-by":"crossref","first-page":"SI252","DOI":"10.1093\/rheumatology\/kead243","article-title":"HBV reactivation in patients with rheumatoid arthritis treated with anti-interleukin-6: a systematic review and meta-analysis","volume":"62","author":"Katelani","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jhep.2025.03.018_bib595","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2018-04-848044","article-title":"Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy","volume":"133","author":"Kusumoto","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2025.03.018_bib596","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184550","article-title":"Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: the Preblin study","volume":"12","author":"Buti","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2025.03.018_bib597","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1038\/s41598-020-59406-4","article-title":"Moderate risk of hepatitis B virus reactivation in HBsAg-\/HBcAb+ carriers receiving rituximab for rheumatoid arthritis","volume":"10","author":"Kuo","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2025.03.018_bib598","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/hep.32241","article-title":"Risk of HBV reactivation during therapies for HCC: a systematic review","volume":"75","author":"Papatheodoridi","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib599","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122041","article-title":"Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma","volume":"10","author":"Jang","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jhep.2025.03.018_bib600","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1743-7563.2012.01534.x","article-title":"Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy","volume":"8","author":"Peng","year":"2012","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.03.018_bib601","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/liv.12112","article-title":"Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma","volume":"33","author":"Lao","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib602","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jamcollsurg.2016.11.009","article-title":"Antiviral therapy inhibits viral reactivation and improves survival after repeat hepatectomy for hepatitis B virus-related recurrent hepatocellular carcinoma","volume":"224","author":"Huang","year":"2017","journal-title":"J Am Coll Surgeons"},{"key":"10.1016\/j.jhep.2025.03.018_bib603","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3350\/cmh.2016.0054","article-title":"Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization","volume":"22","author":"Yoo","year":"2016","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib604","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/jhep.2002.35068","article-title":"Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation","volume":"36","author":"Lau","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib605","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1111\/cas.14846","article-title":"Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy","volume":"112","author":"Yamauchi","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jhep.2025.03.018_bib606","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jcv.2013.03.010","article-title":"Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis","volume":"57","author":"Dong","year":"2013","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jhep.2025.03.018_bib607","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","article-title":"Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors","volume":"62","author":"Yeo","year":"2000","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2025.03.018_bib608","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/liv.13953","article-title":"Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B","volume":"39","author":"Wong","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib609","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/RHU.0000000000000434","article-title":"Safety of corticosteroid treatment in rheumatologic patients with markers of hepatitis B viral infection: pilot evaluation study","volume":"22","author":"Braun-Moscovici","year":"2016","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib610","article-title":"Hepatitis B reactivation in PsA patients: an SLR and meta-analysis for IL-17, IL-23 and JAK inhibitors","author":"Androutsakos","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jhep.2025.03.018_bib611","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1007\/s10067-023-06630-8","article-title":"Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection","volume":"42","author":"Liu","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib612","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2340\/00015555-2989","article-title":"Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study","volume":"98","author":"Chiu","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jhep.2025.03.018_bib613","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3390\/jcm12010231","article-title":"Reactivation of hepatitis B virus in lung cancer patients receiving tyrosine kinase inhibitor treatment","volume":"12","author":"Lee","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib614","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/bmt.2010.70","article-title":"Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT","volume":"46","author":"Vigan\u00f2","year":"2011","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.jhep.2025.03.018_bib615","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.ekir.2023.05.005","article-title":"Hepatitis B virus reactivation in kidney transplant recipients treated with Belatacept","volume":"8","author":"Schwarz","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jhep.2025.03.018_bib616","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/jcm12010086","article-title":"The impact of b\/tsDMARD dose reduction on chronic hepatitis B in rheumatoid arthritis patients: a two-center long-term safety analysis","volume":"12","author":"Chen","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib617","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/10245332.2017.1321882","article-title":"Hepatitis B reactivation in patients receiving targeted therapies","volume":"22","author":"Chang","year":"2017","journal-title":"Hematology"},{"key":"10.1016\/j.jhep.2025.03.018_bib618","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1001\/jama.2014.15704","article-title":"Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial","volume":"312","author":"Huang","year":"2014","journal-title":"JAMA - J Am Med Assoc"},{"key":"10.1016\/j.jhep.2025.03.018_bib619","doi-asserted-by":"crossref","first-page":"30642","DOI":"10.18632\/oncotarget.8907","article-title":"Systematic review with network meta-analysis: comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2025.03.018_bib620","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.3324\/haematol.2017.168609","article-title":"Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies: two case reports","volume":"102","author":"Grossi","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jhep.2025.03.018_bib621","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184550","article-title":"Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: the Preblin study","volume":"12","author":"Buti","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jhep.2025.03.018_bib622","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s12072-023-10635-5","article-title":"Preventing viral relapse with prophylactic tenofovir in hepatitis B carriers receiving chemotherapy: a phase IV randomized study in Taiwan","volume":"18","author":"Hsu","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib623","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.leukres.2016.09.014","article-title":"Delayed HBV reactivation in rituximab-containing chemotherapy: how long should we continue anti-virus prophylaxis or monitoring HBV-DNA?","volume":"50","author":"Nakaya","year":"2016","journal-title":"Leuk Res"},{"key":"10.1016\/j.jhep.2025.03.018_bib624","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.14309\/ajg.0000000000002185","article-title":"A prospective study of preemptive tenofovir disoproxil fumarate therapy in HBsAg-positive patients with diffuse large B-cell lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, Vincristine, and Prednisone","volume":"118","author":"Kim","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib625","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJM199312163292503","article-title":"Liver transplantation in European patients with the hepatitis B surface antigen","volume":"329","author":"Samuel","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib626","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/apt.16374","article-title":"2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation","volume":"54","author":"Duvoux","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib627","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0016-5085(92)90182-X","article-title":"High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis","volume":"102","author":"Lau","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib628","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0168-8278(01)00080-0","article-title":"Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis","volume":"34","author":"Marzano","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib629","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1600-6143.2012.04315.x","article-title":"High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis b virus recurrence after liver transplantation: a systematic review","volume":"13","author":"Cholongitas","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2025.03.018_bib630","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhep.2012.10.016","article-title":"Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes","volume":"58","author":"Burra","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib631","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1097\/TP.0000000000001171","article-title":"Early introduction of subcutaneous hepatitis B immunoglobulin following liver transplantation for hepatitis B virus infection: a prospective, multicenter study","volume":"100","author":"De Simone","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2025.03.018_bib632","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/14787210.2016.1220831","article-title":"Comparative efficacy of oral nucleotide analogues for the prophylaxis of hepatitis B virus recurrence after liver transplantation: a network meta-analysis","volume":"14","author":"Zheng","year":"2016","journal-title":"Expert Rev Anti-Infective Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib633","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/tid.12434","article-title":"Tenofovir\/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients","volume":"17","author":"Fern\u00e1ndez","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib634","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/tid.12369","article-title":"Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis?","volume":"17","author":"Choudhary","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib635","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.dld.2018.03.032","article-title":"Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: a 5-year follow-up study after hepatitis B immunoglobulin withdrawal","volume":"50","author":"Manini","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib636","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10620-009-0999-6","article-title":"HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients","volume":"55","author":"Weber","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2025.03.018_bib637","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/lt.21041","article-title":"Low risk of hepatitits B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy","volume":"13","author":"Wong","year":"2007","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jhep.2025.03.018_bib638","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ajg.2013.111","article-title":"Oral nucleoside\/nucleotide analogs without hepatitis b immune globulin after liver transplantation for hepatitis b","volume":"108","author":"Fung","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib639","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/ajg.2013.122","article-title":"Editorial: prophylaxis in hbv-infected liver transplant patients: end of the HBIG era?","volume":"108","author":"Terrault","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib640","article-title":"Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jhep.2025.03.018_bib641","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1111\/liv.13858","article-title":"Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation","volume":"38","author":"Lens","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib642","first-page":"312","article-title":"HBIG remains significant in the era of new potent nucleoside analogues for prophylaxis against hepatitis B recurrence after liver transplantation","volume":"35","author":"Kasraianfard","year":"2016","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.jhep.2025.03.018_bib643","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1097\/TP.0000000000001786","article-title":"Short course of postoperative hepatitis B immunoglobulin plus antivirals prevents reinfection of liver transplant recipients","volume":"101","author":"Radhakrishnan","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2025.03.018_bib644","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/lt.23628","article-title":"Randomized trial of emtricitabine\/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation","volume":"19","author":"Teperman","year":"2013","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jhep.2025.03.018_bib645","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/hep.29191","article-title":"Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: results up to 8 years","volume":"66","author":"Fung","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib646","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jhep.2011.06.016","article-title":"Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation","volume":"56","author":"Mederacke","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib647","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1097\/TP.0000000000004138","article-title":"Liver transplantation in hepatitis B\/hepatitis D (delta) virus coinfected recipients","volume":"106","author":"Martini","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2025.03.018_bib649","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/hep.28321","article-title":"Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma","volume":"63","author":"Ag\u00fcero","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib650","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/cid\/ciac821","article-title":"Improved survival after liver transplantation for patients with human immunodeficiency virus (HIV) and HIV\/hepatitis C virus coinfection in the integrase strand transfer inhibitor and direct-acting antiviral eras","volume":"76","author":"Jacob","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib651","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1053\/j.gastro.2008.02.064","article-title":"Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation","volume":"134","author":"Faria","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib652","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/lt.21882","article-title":"Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation","volume":"15","author":"Saab","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2025.03.018_bib653","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1097\/JS9.0000000000001141","article-title":"Post-transplant hepatitis B virus reactivation impacts the prognosis of patients with hepatitis B-related hepatocellular carcinoma: a dual-centre retrospective cohort study in China","volume":"110","author":"Li","year":"2024","journal-title":"Int J Surg"},{"key":"10.1016\/j.jhep.2025.03.018_bib654","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/liv.15124","article-title":"State of the art treatment of hepatitis B virus hepatocellular carcinoma and the role of hepatitis B surface antigen post-liver transplantation and resection","volume":"42","author":"Schemmer","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib655","article-title":"Liver transplantation for HBV-related liver disease: impact of prophylaxis for HBV on HCC recurrence","author":"Burra","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.018_bib656","doi-asserted-by":"crossref","DOI":"10.1111\/j.1399-0012.2011.01409.x","article-title":"Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts - a systematic analysis","volume":"25","author":"Skagen","year":"2011","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jhep.2025.03.018_bib657","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jhep.2009.11.009","article-title":"Liver grafts from anti-hepatitis B core positive donors: a systematic review","volume":"52","author":"Cholongitas","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib658","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/ajt.13187","article-title":"Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management","volume":"15","author":"Huprikar","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2025.03.018_bib659","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/ajt.12598","article-title":"Lamivudine compared with newer antivirals for prophylaxis of hepatitis B core antibody positive livers: a cost-effectiveness analysis","volume":"14","author":"Wright","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2025.03.018_bib660","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/TP.0b013e3182845f97","article-title":"Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: A 12-year experience","volume":"95","author":"Chang","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2025.03.018_bib661","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s12072-010-9188-0","article-title":"Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers","volume":"4","author":"Chotiyaputta","year":"2010","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2025.03.018_bib662","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/hepr.12249","article-title":"Lamivudine resistance leading to de novo hepatitis B infection in recipients of hepatitis B core antibody positive liver allografts","volume":"44","author":"Leong","year":"2014","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2025.03.018_bib663","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13227","article-title":"The use of hepatitis B immunoglobulin with or without hepatitis B vaccine to prevent de novo hepatitis B in pediatric recipients of anti-HBc\u2013positive livers","volume":"22","author":"Yamashiki","year":"2018","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jhep.2025.03.018_bib664","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188190","article-title":"Active immunization in patients transplanted for hepatitis B virus related liver diseases: a prospective study","volume":"12","author":"Yang","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jhep.2025.03.018_bib665","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/lt.24814","article-title":"Active immunization for prevention of De novo hepatitis B virus infection after adult living donor liver transplantation with a hepatitis B core antigen\u2013positive graft","volume":"23","author":"Wang","year":"2017","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jhep.2025.03.018_bib666","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/hepr.12586","article-title":"Long-term efficacy of hepatitis B vaccination as post-transplant prophylaxis in hepatitis B surface antigen (HBsAg) positive recipients and HBsAg negative recipients of anti-hepatitis B core positive grafts","volume":"46","author":"Yoshizawa","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2025.03.018_bib667","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/lt.24858","article-title":"Vaccination to prevent de novo hepatitis B: Are there patients who do not need antiviral prophylaxis?","volume":"23","author":"Verna","year":"2017","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jhep.2025.03.018_bib668","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1399-3062.2012.00782.x","article-title":"Renal grafts from anti-hepatitis B core-positive donors: a quantitative review of the literature","volume":"14","author":"Mahboobi","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib669","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/tid.12256","article-title":"Prognostic implications of recipient or donor hepatitis B seropositivity in thoracic transplantation: analysis of 426 hepatitis B surface antigen-positive recipients","volume":"16","author":"Manickam","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib670","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/00007890-199708150-00011","article-title":"Risks of transplanting kidneys from hepatitis B surface antigen- negative, hepatitis B core antibody-positive donors","volume":"64","author":"Satterthwaite","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2025.03.018_bib671","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10096-013-1982-x","article-title":"Safety of hematopoietic stem cell transplantation from hepatitis B core antibodies-positive donors with low\/undetectable viremia in HBV-na\u00efve children","volume":"33","author":"Frange","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib672","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3026(18)30152-2","article-title":"Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review","volume":"5","author":"Lu","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jhep.2025.03.018_bib673","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jhep.2014.05.003","article-title":"Safe use of liver grafts from hepatitis B surface antigen positive donors in liver transplantation","volume":"61","author":"Yu","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib674","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2024.07.032","article-title":"EASL clinical practice guidelines on liver transplantation","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib675","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1111\/ajt.12921","article-title":"The outcomes of kidney transplantation in hepatitis B surface antigen (HBsAg)-negative recipients receiving graft from HBsAg-positive donors: a retrospective, propensity score-matched study","volume":"14","author":"Chancharoenthana","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2025.03.018_bib676","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/j.1600-6143.2009.02707.x","article-title":"Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: a prospective nonrandomized controlled study from a single center","volume":"9","author":"Jiang","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2025.03.018_bib677","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/blood.V96.2.452.014k13_452_458","article-title":"A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation","volume":"96","author":"Lau","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2025.03.018_bib678","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/j.1600-6143.2005.00887.x","article-title":"Effectiveness of prophylactic anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors","volume":"5","author":"Hui","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2025.03.018_bib679","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/tid.12094","article-title":"Renal transplantation from hepatitis B surface antigen (HBsAg)-positive donors to HBsAg-negative recipients: a case of post-transplant fulminant hepatitis associated with an extensively mutated hepatitis B virus strain and review of the current literature","volume":"15","author":"Magiorkinis","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib680","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.bbmt.2009.12.533","article-title":"Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation","volume":"16","author":"Giaccone","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jhep.2025.03.018_bib681","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/apt.17120","article-title":"Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma","volume":"56","author":"Wong","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib682","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1053\/j.gastro.2016.05.048","article-title":"Long-term effects of hepatitis B immunization of infants in preventing liver cancer","volume":"151","author":"Chang","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.03.018_bib683","article-title":"Antenatal administration of hepatitis B immunoglobulin and hepatitis B vaccine to prevent mother to child transmission in hepatitis B virus surface antigen positive pregnant women: a systematic review and meta-analysis","volume":"99","author":"Chen","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhep.2025.03.018_bib684","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1016\/j.vaccine.2016.08.027","article-title":"Hepatitis B vaccine response in obesity: a meta-analysis","volume":"34","author":"Fan","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2025.03.018_bib685","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.1942","article-title":"Response to hepatitis B vaccination in patients with liver cirrhosis","volume":"27","author":"Aggeletopoulou","year":"2017","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.jhep.2025.03.018_bib686","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/14760584.2023.2289566","article-title":"Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analyses","volume":"23","author":"Qiu","year":"2024","journal-title":"Expert Rev Vaccin"},{"key":"10.1016\/j.jhep.2025.03.018_bib687","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/14760584.2020.1760098","article-title":"Diabetes mellitus as a vaccine-effect modifier: a review","volume":"19","author":"Verstraeten","year":"2020","journal-title":"Expert Rev Vaccin"},{"key":"10.1016\/j.jhep.2025.03.018_bib688","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/j.vaccine.2017.03.080","article-title":"Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"35","author":"Jiang","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2025.03.018_bib689","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3390\/vaccines12070710","article-title":"A comprehensive review of hepatitis B vaccine nonresponse and associated risk factors","volume":"12","author":"Tahir","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jhep.2025.03.018_bib690","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.vaccine.2018.02.036","article-title":"Hepatitis B vaccination and the putative risk of central demyelinating diseases \u2013 a systematic review and meta-analysis","volume":"36","author":"Mouchet","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2025.03.018_bib691","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.356.6345.1320","article-title":"Europe\u2019s top court alarms vaccine experts","volume":"356","author":"Vogel","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jhep.2025.03.018_bib692","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/AOG.0b013e3182148efe","article-title":"Efficacy of an accelerated hepatitis b vaccination program during pregnancy","volume":"117","author":"Sheffield","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jhep.2025.03.018_bib693","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/14760584.2023.2274482","article-title":"PreHevbrio: the first approved 3-antigen hepatitis B vaccine","volume":"22","author":"Vesikari","year":"2023","journal-title":"Expert Rev Vaccin"},{"key":"10.1016\/j.jhep.2025.03.018_bib694","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.28652","article-title":"Immunogenicity and safety of a 3-antigen hepatitis B vaccine vs a single-antigen hepatitis B vaccine: a phase 3 randomized clinical trial","volume":"4","author":"Vesikari","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhep.2025.03.018_bib695","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S1473-3099(20)30780-5","article-title":"Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial","volume":"21","author":"Vesikari","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib696","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1016\/j.vaccine.2023.05.010","article-title":"The persistence of seroprotective levels of antibodies after vaccination with PreHevbrio, a 3-antigen hepatitis B vaccine","volume":"41","author":"Vesikari","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2025.03.018_bib697","first-page":"143","article-title":"Immunogenicity of Sci-B-vac (a third-generation hepatitis B vaccine) in HIV-positive adults","volume":"19","author":"Alon","year":"2017","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.jhep.2025.03.018_bib698","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/ecco-jcc\/jjw046","article-title":"Sci-B-VacTM vs engerix-B vaccines for hepatitis B virus in patients with inflammatory bowel diseases: a randomised controlled trial","volume":"10","author":"Etzion","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jhep.2025.03.018_bib699","doi-asserted-by":"crossref","first-page":"c67","DOI":"10.1159\/000078403","article-title":"Improved immunogenicity of a novel third-generation recombinant hepatitis B vaccine in patients with end-stage renal disease","volume":"97","author":"Weinstein","year":"2004","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.jhep.2025.03.018_bib700","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10157-017-1416-7","article-title":"A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS\/S hepatitis B vaccine Sci-B-VacTM, as compared to Engerix B\u00ae, among vaccine na\u00efve and vaccine non-responder dialysis patients","volume":"22","author":"Elhanan","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jhep.2025.03.018_bib701","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jama.2018.1097","volume":"319","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2025.03.018_bib702","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.vaccine.2012.01.087","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2025.03.018_bib703","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1016\/j.vaccine.2013.05.068","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age","volume":"31","author":"Heyward","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2025.03.018_bib704","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.vaccine.2017.12.038","article-title":"Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2025.03.018_bib705","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2136912","volume":"18","author":"Girndt","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jhep.2025.03.018_bib706","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1016\/j.vaccine.2021.05.003","article-title":"An open-label, single-arm study evaluating the immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B\u00ae) in adults receiving hemodialysis","volume":"39","author":"Awad","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2025.03.018_bib707","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad267","article-title":"Observational study evaluating the seroprotection of HepB-alum vaccine and HepB-CpG vaccine in people with HIV","volume":"10","author":"Reilly-Evans","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib708","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/cid\/ciad201","article-title":"Immunogenicity and safety of hepatitis B virus (HBV) vaccine with a toll-like receptor 9 agonist adjuvant in HBV vaccine-na\u00efve people with human immunodeficiency virus","volume":"77","author":"Marks","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib709","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/QAI.0000000000002573","article-title":"Brief report: Heplisav-B seroprotection in people with HIV: a single-center experience","volume":"86","author":"Schnittman","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jhep.2025.03.018_bib710","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/QAD.0000000000002813","article-title":"Hepatitis B vaccination response and safety in people living with HIV\/AIDS receiving HepB-CpG series","volume":"35","author":"Preininger","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2025.03.018_bib711","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1016\/j.vaccine.2021.09.050","article-title":"Serological response with Heplisav-B\u00ae in prior Hepatitis B vaccine non-responders living with HIV","volume":"39","author":"Khaimova","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2025.03.018_bib712","doi-asserted-by":"crossref","first-page":"8","DOI":"10.21037\/tgh-22-12","article-title":"Efficacy of a two-dose hepatitis B vaccination with a novel immunostimulatory sequence adjuvant (Heplisav-B) on patients with chronic liver disease: a retrospective study","volume":"8","author":"Kwon","year":"2023","journal-title":"Transl Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib713","article-title":"Two-dose hepatitis B vaccine (Heplisav-B) results in better seroconversion than three-dose vaccine (Engerix-B) in chronic liver disease","author":"Amjad","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2025.03.018_bib714","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/ibd\/izac079","article-title":"Efficacy of hepatitis B vaccination with a novel immunostimulatory sequence adjuvant (Heplisav-B) in patients with inflammatory bowel disease","volume":"29","author":"Kwon","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib715","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.vaccine.2022.04.027","article-title":"Safety and immunogenicity of HepB-CpG in women with documented pregnancies post-vaccination: a retrospective chart review","volume":"40","author":"Kushner","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2025.03.018_bib716","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.vaccine.2018.03.067","article-title":"Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults","volume":"36","author":"Hyer","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2025.03.018_bib717","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2022.2540","article-title":"Association between 2-dose vs 3-dose hepatitis B vaccine and acute myocardial infarction","volume":"327","author":"Bruxvoort","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2025.03.018_bib718","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1016\/j.vaccine.2023.06.004","article-title":"Post-licensure safety study of new-onset immune-mediated diseases, herpes zoster, and anaphylaxis in adult recipients of HepB-CpG vaccine versus HepB-alum vaccine","volume":"41","author":"Ackerson","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2025.03.018_bib719","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6701a1","article-title":"Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jhep.2025.03.018_bib720","doi-asserted-by":"crossref","first-page":"477","DOI":"10.15585\/mmwr.mm7113a1","article-title":"Universal hepatitis B vaccination in adults aged 19-59 Years: updated recommendations of the advisory committee on immunization practices - United States, 2022","volume":"71","author":"Weng","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jhep.2025.03.018_bib721","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1002\/hep.31991","article-title":"Prevalence of HBV infection, vaccine-induced immunity, and susceptibility among at-risk populations: US households, 2013-2018","volume":"74","author":"Roberts","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib722","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss7003a1","article-title":"Surveillance of vaccination coverage among adult populations -United States, 2018","volume":"70","author":"Lu","year":"2021","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.jhep.2025.03.018_bib723","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/bmj.38719.435833.7C","article-title":"Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis","volume":"332","author":"Lee","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2025.03.018_bib724","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.vaccine.2014.01.099","article-title":"Hepatitis B vaccine response among infants born to hepatitis B surface antigen-positive women","volume":"32","author":"Ko","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2025.03.018_bib725","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/01.inf.0000073123.93220.a8","article-title":"Role of hepatitis B immunoglobulin in infants born to hepatitis B e antigen-negative carrier mothers in Taiwan","volume":"22","author":"Yang","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jhep.2025.03.018_bib726","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/jac\/dku404","article-title":"Hepatitis B vaccine alone or with hepatitis B immunoglobulin in neonates of HBsAg+\/HBeAg- mothers: a systematic review and meta-analysis","volume":"70","author":"Machaira","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jhep.2025.03.018_bib727","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.vaccine.2012.12.012","article-title":"Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review","volume":"31","author":"Schillie","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2025.03.018_bib728","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3390\/vaccines9070801","article-title":"Timely birth dose vaccine to prevent vertical transmission of hepatitis B: a single center experience on the road to the WHO elimination goals in Italy","volume":"9","author":"Pinon","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jhep.2025.03.018_bib729","doi-asserted-by":"crossref","first-page":"e3317","DOI":"10.1093\/cid\/ciaa898","article-title":"Increased protection of earlier use of immunoprophylaxis in preventing perinatal transmission of hepatitis B virus","volume":"73","author":"Huang","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib730","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1086\/314578","article-title":"What level of hepatitis B antibody is protective?","volume":"179","author":"Jack","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib731","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1016\/0002-9343(89)90525-1","article-title":"Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine","volume":"87","author":"Andr\u00e9","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib732","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1007\/s10067-020-05042-2","article-title":"Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: results of the RIER cohort study","volume":"39","author":"Richi","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib733","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1016\/j.vaccine.2023.06.041","article-title":"Vaccination with HepB-CpG vaccine in individuals undergoing immune suppressive drug therapy","volume":"41","author":"Perrillo","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2025.03.018_bib734","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/ibd\/izaa353","article-title":"Hepatitis-B vaccine response in inflammatory bowel disease patients: a systematic review and meta-analysis","volume":"27","author":"Kochhar","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib735","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0002-9343(97)00132-0","article-title":"Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial","volume":"103","author":"Rosman","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib736","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1016\/j.vaccine.2013.05.067","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease","volume":"31","author":"Janssen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2025.03.018_bib737","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100775","article-title":"Vaccination for patients receiving dialysis","volume":"6","author":"Sam","year":"2024","journal-title":"Kidney Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib738","series-title":"Prevention and management of hepatitis B virus infection in adults with HIV","author":"Gupta","year":"2022"},{"key":"10.1016\/j.jhep.2025.03.018_bib739","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamainternmed.2016.0741","article-title":"Long-term immune response to hepatitis B virus vaccination regimens in adults with human immunodeficiency virus 1 secondary analysis of a randomized clinical trial","volume":"176","author":"Launay","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib740","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/jama.2011.351","article-title":"Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial","volume":"305","author":"Launay","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2025.03.018_bib741","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1310\/hct1105-332","article-title":"Factors associated with seroconversion after standard dose hepatitis B vaccination and high-dose revaccination among HIV-infected patients","volume":"11","author":"Pettit","year":"2010","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.jhep.2025.03.018_bib742","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/0956462412472309","article-title":"Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard dose vaccination: a meta-analysis?","volume":"24","author":"Ni","year":"2013","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.jhep.2025.03.018_bib743","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1473-3099(15)00220-0","article-title":"Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial","volume":"15","author":"Rey","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2025.03.018_bib744","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1016\/j.vaccine.2006.06.079","article-title":"Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (na\u00efve) and CD45RO+ (memory) subsets in HIV-1-infected subjects","volume":"24","author":"Veiga","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2025.03.018_bib745","doi-asserted-by":"crossref","first-page":"8206","DOI":"10.1016\/j.vaccine.2020.10.067","article-title":"Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations","volume":"38","author":"Rosenthal","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2025.03.018_bib746","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/21645515.2019.1574151","article-title":"High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: a pilot study","volume":"15","author":"Haykir Solay","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jhep.2025.03.018_bib747","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/j.1365-2036.2012.05110.x","article-title":"Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease","volume":"35","author":"Gisbert","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.03.018_bib748","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/ajg.2012.79","article-title":"Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease","volume":"107","author":"Gisbert","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.03.018_bib749","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jhep.2014.08.010","article-title":"Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance","volume":"61","author":"Albillos","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib750","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/jvh.13509","article-title":"Efficacy of an accelerated double-dose hepatitis B vaccine regimen in patients with cirrhosis","volume":"28","author":"Rodr\u00edguez-Tajes","year":"2021","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.03.018_bib751","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/gutjnl-2022-328222","article-title":"Three double-dose reinforced hepatitis B revaccination scheme for patients with cirrhosis unresponsive to the standard regimen: an open-label randomised clinical trial","volume":"73","author":"Gir\u00e1ldez-Gallego","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.03.018_bib752","first-page":"1","article-title":"Immunization of health-care personnel recommendations of the advisory committee on immunization practices (ACIP) morbidity and mortality weekly report","volume":"60","year":"2011","journal-title":"Mmwr"},{"key":"10.1016\/j.jhep.2025.03.018_bib753","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0168-8278(88)80032-1","article-title":"Persistence of specific antibodies after hepatitis B vaccination","volume":"6","author":"Jilg","year":"1988","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib754","doi-asserted-by":"crossref","first-page":"333","DOI":"10.7326\/0003-4819-142-5-200503010-00008","article-title":"Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up","volume":"142","author":"McMahon","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib755","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/hep.510290349","article-title":"Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen","volume":"29","author":"Huang","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib756","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(05)67568-X","article-title":"Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study","volume":"366","author":"Zanetti","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.03.018_bib757","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058029","article-title":"Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster dose","volume":"8","author":"Mendy","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2025.03.018_bib758","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1055\/s-0031-1273462","article-title":"Prophylaxis, diagnosis and therapy of hepatitis B virus infection the German guideline","volume":"49","author":"Cornberg","year":"2011","journal-title":"Z Gastroenterologie"},{"key":"10.1016\/j.jhep.2025.03.018_bib759","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/INF.0000000000000994","article-title":"Markers of protection in children and adolescents six to fourteen years after primary hepatitis B vaccination in real life: a pilot study","volume":"35","author":"Brunskole Hummel","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jhep.2025.03.018_bib760","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/hep.32474","article-title":"Protection and antibody levels 35 years after primary series with hepatitis B vaccine and response to a booster dose","volume":"76","author":"Bruce","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib761","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJMoa1007644","article-title":"Nucleic acid testing to detect HBV infection in blood donors","volume":"364","author":"Stramer","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib762","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/JCM.02430-07","article-title":"Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen","volume":"46","author":"Huzly","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jhep.2025.03.018_bib763","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.4161\/hv.21818","article-title":"Revaccination of non- and low- responders after a standard three dose hepatitis B vaccine schedule","volume":"8","author":"Han","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jhep.2025.03.018_bib764","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0264-410X(96)00205-8","article-title":"Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule--results of a post-marketing surveillance","volume":"15","author":"Clemens","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2025.03.018_bib765","doi-asserted-by":"crossref","first-page":"6564","DOI":"10.1016\/j.vaccine.2015.09.051","article-title":"A systematic review and meta-analysis of management options for adults who respond poorly to hepatitis B vaccination","volume":"33","author":"David","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2025.03.018_bib766","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of bepirovirsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib767","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1056\/NEJMoa2405485","article-title":"Xalnesiran with or without an immunomodulator in chronic hepatitis B","volume":"391","author":"Hou","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib768","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra2211764","article-title":"New approaches to chronic hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib769","article-title":"AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B","author":"Shin","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib770","article-title":"Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis","volume":"4","author":"Wong","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.03.018_bib771","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jhep.2024.08.016","article-title":"A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B","volume":"82","author":"Hur","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib772","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jhep.2021.09.025","article-title":"An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B","volume":"76","author":"Kim","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib773","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.jhep.2015.07.009","article-title":"Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: a propensity score landmark analysis","volume":"63","author":"Hsiang","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.03.018_bib774","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1097\/HEP.0000000000000404","article-title":"SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: a territory-wide cohort study in Hong Kong","volume":"78","author":"Lee","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib775","doi-asserted-by":"crossref","first-page":"E931","DOI":"10.1503\/cmaj.240003","article-title":"Renin-angiotensin system inhibitors and risk of hepatocellular carcinoma among patients with hepatitis B virus infection","volume":"196","author":"Chen","year":"2024","journal-title":"CMAJ"},{"key":"10.1016\/j.jhep.2025.03.018_bib776","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep.32380","article-title":"Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis","volume":"76","author":"Jang","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.03.018_bib777","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa1912035","article-title":"Association of aspirin with hepatocellular carcinoma and liver-related mortality","volume":"382","author":"Simon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.018_bib778","article-title":"Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis","volume":"57","author":"Wang","year":"2025","journal-title":"Ann Med"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825001746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825001746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T21:11:52Z","timestamp":1773349912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827825001746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":775,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0168827825001746"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2025.03.018","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}